Maternal Transmission Ratio Distortion of GNAS Loss‐of‐Function Mutations
13-01-2020 – Sarah Snanoudj, Arnaud Molin, Cindy Colson, Nadia Coudray, Sylvie Paulien, Hervé Mittre, Marion Gérard, Elise Schaefer, Alice Goldenberg, Justine Bacchetta, Sylvie Odent, Sophie Naudion, Bénédicte Demeer, Laurence Faivre, Nicolas Gruchy, Marie‐Laure Kottler, Nicolas Richard
ABSTRACTPseudohypoparathyroidism type 1A (PHP1A) and pseudopseudohypoparathyroidism (PPHP) are two rare autosomal dominant disorders caused by loss‐of‐function mutations in the imprinted Guanine Nucleotide Binding Protein, Alpha Stimulating Activity (GNAS) gene, coding Gsα. PHP1A is caused by mutations in the maternal allele and results in Albrights hereditary osteodystrophy (AHO) and hormonal resistance, mainly to the parathormone (PTH), whereas PPHP, with AHO features and no hormonal resistance, is linked to mutations in the paternal allele. This study sought to investigate parental transmission of GNAS mutations. We conducted a retrospective study in a population of 204 families with 361 patients harboring GNAS mutations. To prevent ascertainment bias toward a higher proportion of affected children due to the way in which data were collected, we excluded from transmission analysis all probands in the ascertained sibships. After bias correction, the distribution ratio of the mutated alleles was calculated from the observed genotypes of the offspring of nuclear families and was compared to the expected ratio of 50% according to Mendelian inheritance (one‐sample Z‐test). Sex ratio, phenotype of the transmitting parent, and transmission depending on the severity of the mutation were also analyzed. Transmission analysis was performed in 114 nuclear families and included 250 descendants. The fertility rates were similar between male and female patients. We showed an excess of transmission from mother to offspring of mutated alleles (59%, p = .022), which was greater when the mutations were severe (61.7%, p = .023). Similarly, an excess of transmission was found when the mother had a PHP1A phenotype (64.7%, p = .036). By contrast, a Mendelian distribution was observed when the mutations were paternally inherited. Higher numbers of females within the carriers, but not in noncarriers, were also observed. The mother‐specific transmission ratio distortion (TRD) and the sex‐ratio imbalance associated to PHP1A point to a role of Gsα in oocyte biology or embryogenesis, with implications for genetic counseling. © 2019 American Society for Bone and Mineral Research.
Propranolol Reverses Impaired Fracture Healing Response Observed With Selective Serotonin Reuptake Inhibitor Treatment
10-01-2020 – Sooyeon Lee, Lindsey H Remark, Daniel B Buchalter, Anne M Josephson, Madeleine Z Wong, Hannah P Litwa, Rivka Ihejirika, Kevin Leclerc, Danielle Markus, Nury L Yim, Ruchi Tejwani, Vivian Bradaschia‐Correa, Philipp Leucht
ABSTRACTSelective serotonin reuptake inhibitors (SSRIs) are one of the most commonly prescribed antidepressants worldwide and recent data show significant impairment of fracture healing after treatment with the SSRI fluoxetine in mice. Here, we provide evidence that the negative effects of SSRIs can be overcome by administration of the beta‐blocker propranolol at the time of fracture. First, in vitro experiments established that propranolol does not affect osteogenic differentiation. We then used a murine model of intramembranous ossification to study the potential rescue effect of propranolol on SSRI‐induced impaired fracture healing. Micro‐CT analysis revealed that fluoxetine treatment resulted in a smaller bony regenerate and that this decrease in bone formation can be overcome by co‐treatment with propranolol. We then tested this in a clinically relevant model of endochondral ossification. Fluoxetine‐treated mice with a femur fracture were treated with propranolol initiated at the time of fracture, and a battery of analyses demonstrated a reversal of the detrimental effect of fluoxetine on fracture healing in response to propranolol treatment. These experiments show for the first time to our knowledge that the negative effects of SSRIs on fracture healing can be overcome by co‐treatment with a beta‐blocker. © 2019 American Society for Bone and Mineral Research.
Effects of Supplemental Vitamin D on Bone Health Outcomes in Women and Men in the VITamin D and OmegA‐3 TriaL (VITAL)
10-01-2020 – Meryl S. LeBoff, Sharon H. Chou, Elle M. Murata, Catherine M. Donlon, Nancy R. Cook, Samia Mora, I‐Min Lee, Gregory Kotler, Vadim Bubes, Julie E. Buring, JoAnn E. Manson
ABSTRACTAlthough supplemental vitamin D is used to promote bone health in the general population, data from randomized controlled trials (RCTs) have been inconsistent. We determined whether daily, vitamin D3 supplementation improves bone mineral density (BMD) and/or structure. VITamin D and Omeg
L (VITAL) is a double‐blind, placebo‐controlled RCT of supplemental vitamin D3 (2,000 IU/day) and/or omega‐3 fatty acids (1 g/day) in 25,871 adults nationwide. This ancillary study included a subcohort of 771 participants (men ≥50 and women ≥55 years; not taking bone active medications) evaluated at baseline and 2‐years follow‐up (89% retention). Total 25(OH)D levels were measured by liquid chromatography tandem mass spectrometry (Quest Diagnostics, CA). Free 25(OH)D (FVD) levels were measured using the ELISA assay by Future Diagnostics Solutions B.
V. (Wijchen Netherlands). Primary endpoints were 2‐year changes in areal (a)BMD at the spine, hip, and whole body determined by dual‐energy X‐ray absorptiometry. Secondary endpoints were 2‐year changes in volumetric (v)BMD and cortical thickness at the radius and tibia assessed by peripheral quantitative computed tomography. Supplemental vitamin D3 vs. placebo had no effect on 2‐year changes in a
BMD at the spine (0.33% vs. 0.17%; p = 0.55), femoral neck (−0.27% vs. ‐0.68%; p = 0.16), total hip (−0.76% vs. ‐0.95%; p = 0.23), or whole body (−0.22% vs. ‐0.15%; p = 0.60), or on measures of bone structure. Effects did not vary by sex, race/ethnicity, BMI, or 25(OH)D levels. Among participants with baseline FVD levels below the median (<14.2 pmol/L), there was a slight increase in spine a
BMD (0.75% vs. 0%; p = 0.043) and attenuation in loss of total hip a
BMD (−0.42% vs. ‐0.98%; p = 0.044) with vitamin D3. Whether baseline FVD levels help to identify those more likely to benefit from supplementation warrants further study. Supplemental vitamin D3 vs. placebo for two years in general healthy adults not selected for vitamin D insufficiency did not improve BMD or structure.
This article is protected by copyright. All rights reserved.
Rac1 Inhibition Via Srgap2 Restrains Inflammatory Osteoclastogenesis and Limits the Clastokine, SLIT3
09-01-2020 – Bongjin Shin, Justine Kupferman, Ewoud Schmidt, Franck Polleux, Anne M Delany, Sun‐Kyeong Lee
ABSTRACTThe Rac1‐specific guanosine triphosphatase (GTPase)‐activating protein Slit‐Robo GAP2 (Srgap2) is dramatically upregulated during RANKL‐induced osteoclastogenesis. Srgap2 interacts with the cell membrane to locally inhibit activity of Rac1. In this study, we determined the role of Srgap2 in the myeloid lineage on bone homeostasis and the osteoclastic response to TNFα treatment. The bone phenotype of mice specifically lacking Srgap2 in the myeloid lineage (Srgap2 f/f:Lys
M‐Cre; Srgap2 conditional knockout c
KO) was investigated using histomorphometric analysis, in vitro cultures and Western blot analysis. Similar methods were used to determine the impact of TNFα challenge on osteoclast formation in Srgap2 c
KO mice. Bone parameters in male Srgap2 c
KO mice were unaffected. However, female c
KO mice displayed higher trabecular bone volume due to increased osteoblast surface and bone formation rate, whereas osteoclastic parameters were unaltered. In vitro, cells from Srgap2 c
KO had strongly enhanced Rac1 activation, but RANKL‐induced osteoclast formation was unaffected. In contrast, conditioned medium from Srgap2 c
KO osteoclasts promoted osteoblast differentiation and had increased levels of the bone anabolic clastokine SLIT3, providing a possible mechanism for increased bone formation in vivo. Rac1 is rapidly activated by the inflammatory cytokine TNFα. Supracalvarial injection of TNFα caused an augmented osteoclastic response in Srgap2 c
KO mice. In vitro, cells from Srgap2 c
KO mice displayed increased osteoclast formation in response to TNFα. We conclude that Srgap2 plays a prominent role in limiting osteoclastogenesis during inflammation through Rac1, and restricts expression of the paracrine clastokine SLIT3, a positive regulator of bone formation. © 2019 American Society for Bone and Mineral Research.
BMP9 reduces bone loss in ovariectomized mice by dual regulation of bone remodeling
08-01-2020 – Yan‐man Zhou, Yu‐ying Yang, Yi‐xuan Jing, Tian‐jiao Yuan, Li‐hao Sun, Bei Tao, Jian‐min Liu, Hong‐yan Zhao
Bone remodeling is dynamic and is tightly regulated through bone resorption dominated by osteoclasts and bone formation dominated by osteoblasts. Imbalances in this process can cause various pathological conditions, such as osteoporosis. BMP9, a biomolecule produced and secreted by the liver, has many pharmacological effects, including anti‐liver fibrosis, antitumor, anti‐heart failure and antidiabetic activities. However, the effects of BMP9 on the regulation of osteoblast and osteoclast functions and the underlying molecular mechanism(s) have not yet been investigated. In this study, BMP9 increased the expression of osteoblastogenic gene markers, such as ALP, Cola1, OCN, RUNX2 and OSX, and ALP activity in MC3T3‐E1 cells by upregulating LGR6 and activating the Wnt/β‐catenin pathway. BMP9 also suppressed receptor activator of nuclear factor‐κB (NF‐κB) ligand (RANKL)‐induced osteoclast differentiation of bone marrow macrophages (BMMs) by inhibiting the Akt‐NF‐κB‐NFATc1 pathway. More importantly, in an ovariectomy (OVX) mouse model, BMP9 attenuated bone loss and improved bone biomechanical properties in vivo by increasing bone‐forming activity and suppressing bone resorption activity. Accordingly, our current work highlights the dual regulatory effects that BMP9 exerts on bone remodeling by promoting bone anabolic activity and inhibiting osteoclast differentiation in OVX mice.
This article is protected by copyright. All rights reserved.
History of Previous Fracture and Imminent Fracture Risk in Swedish Women Aged 55–90u2009Years Presenting with a Fragility Fracture
08-01-2020 – Emese Toth, Jonas Banefelt, Kristina åkesson, Anna Spångeus, Gustaf Ortsäter, Cesar Libanati
The term “fracture cascade” refers to the sequence of fragility fractures resulting from the increased fracture risk that occurs with aging and following fractures. Here, we evaluate the sequence of previous fractures in women aged 55–90 years presenting with a fragility fracture and subsequent (12–24 months) fracture incidence.
In this retrospective, observational study, women aged 55–90 years with an “index” fragility fracture in 2013 were identified from Swedish national registries. A history of previous fractures (2001–2012) and osteoporosis treatment was used to characterize fracture cascade patterns. Cumulative incidence of new fractures within 12–24 months following the index fracture, based on index fracture type and age, were used to describe the risk of subsequent fractures.35,146 women with a mean age of 73.8 years were included (7,180 hip, 2,786 clinical vertebral, and 25,180 non‐hip/non‐vertebral NHNV index fractures). 38% of women with hip, 38% with clinical vertebral, and 25% with NHNV index fractures had ≥1 previous fracture. Across all index fracture types, the proportion of women with any previous fracture increased with age; 34–46% of index hip or clinical vertebral fractures in women ≥70 years were not their first fracture. Following any index fracture, cumulative incidence of a new fracture over 24 months was over 11% (index clinical vertebral: 18%; index hip: 14%). Osteoporosis treatment rates were low both in patients with (27%) and without (18%) a previous fracture.
These descriptive data demonstrate that almost one‐third of women aged 55–90 years suffering a new fracture have had a previous fragility fracture. Fracture location influences incidence and type of subsequent fracture during the 24 months following a fragility fracture, with clinical vertebral fractures carrying the greatest imminent fracture risk. These data highlight the clinical impact and need for early, effective treatment soon after any fragility fracture.
This article is protected by copyright. All rights reserved.
Increased burden of common risk alleles in children with a significant fracture history
08-01-2020 – Despoina Manousaki, Anders Kämpe, Vince Forgetta, Riikka E Makitie, Ghalib Bardai, Alexandre Belisle, Rui Li, Sture Andersson, Outi Makitie, Frank Rauch, J Brent Richards
Extreme presentations of common disease in children are often presumed to be of Mendelian etiology, but their polygenic basis has not been fully explored. We tested whether children with significant fracture history and no osteogenesis imperfecta (OI) are at increased polygenic risk for fracture. A childhood significant fracture history was defined as the presence of low‐trauma vertebral fractures or multiple long bone fractures. We generated a polygenic score of heel ultrasound derived speed of sound, termed “g
SOS”, which predicts risk of osteoporotic fracture. We tested if individuals from three cohorts with significant childhood fracture history had lower g
SOS. A Canadian cohort included 94 children with suspected Mendelian osteoporosis, of which 68 had negative OI gene panel. Two Finnish cohorts included 59 children with significant fracture history and 22 with suspected Mendelian osteoporosis, among which 18 had no OI. After excluding individuals with OI and ancestral outliers, we generated g
SOS estimates and compared their mean to that of a UK Biobank subset, representing the general population. The average g
SOS across all three cohorts (n=131) was ‐0.47 SD lower than that in UK Biobank (n=80,027, P= 1.1 x 10‐5). The g
SOS of 78 individuals with suspected Mendelian osteoporosis was even lower (‐0.76 SD, P =5.3 x10‐10). Among the 131 individuals with a significant fracture history, we observed 8 individuals with g
SOS below minus 2SD from the mean; their mean lumbar spine DXA‐derived BMD z‐score was ‐1.7 (SD:0.8). In summary, children with significant fracture history but no OI have an increased burden of common risk alleles. This suggests that a polygenic contribution to disease should be considered in children with extreme presentations of fracture.
This article is protected by copyright. All rights reserved.
X‐Linked Hypophosphatemia: Uniquely Mild Disease Associated With PHEX 3′‐UTR Mutation c.*231A>G (A Retrospective Case‐Control Study)
07-01-2020 – Pamela S. Smith, Gary S. Gottesman, Fan Zhang, Fiona Cook, Beatriz Ramirez, Deborah Wenkert, Valerie Wollberg, Margaret Huskey, Steven Mumm, Michael P. Whyte
X‐linked hypophosphatemia (XLH), the most prevalent heritable renal phosphate (Pi) wasting disorder, is caused by deactivating mutations of PHEX. Consequently, circulating phosphatonin FGF23 becomes elevated and hypophosphatemia in affected children leads to rickets with skeletal deformity and reduced linear growth while affected adults suffer from osteomalacia and forms of ectopic mineralization. In 2015, we reported uniquely mild XLH in six children and four of their mothers carrying the non‐coding PHEX 3′‐UTR mutation c.*231A>G. Herein, we characterize this mild XLH variant by comparing its features in 30 individuals to 30 age‐ and sex‐matched patients with XLH but without the 3′‐UTR mutation. The “UTR” and “XLH” groups, both comprising 17 children (2‐17 years, 3 girls) and 13 adults (23‐63 years, 10 women), had mean ages of 23 years. Only 43% of the UTR group versus 90% of the XLH group had received medical treatment for their disorder, including 0% versus 85% of the females, respectively (ps< 0.0001). The UTR group was taller: mean (SD) height Z‐score (HZ) ‐1.0 (1.0) versus ‐2.0 (1.4) (p=0.0034), with significantly greater height for females ‐0.9 (0.7) versus ‐2.3 (1.4), (p=0.0050) but not males ‐1.2 (1.1) versus ‐1.9 (1.5) (p=0.1541), respectively. Mean (SD) “arm span Z‐score” (AZ) did not differ between the UTR ‐0.8 (1.3) versus XLH ‐1.3 (1.8) groups (p=0.2269). Consequently, the UTR group was more proportionate with a mean ∆Z (AZ – HZ) of 0.1 (0.6) versus 0.7 (1.0) (p=0.0158), respectively. Compared to the XLH group, the UTR group had significantly higher fasting serum Pi and Tm
P/GFR (ps≤0.0060), serum FGF23 concentrations within the reference range (p=0.0068), and similar serum alkaline phosphatase levels (p = 0.6513). UTR lumbar spine bone mineral density Z‐score was higher (p=0.0343). Thus, the 3′‐UTR variant of XLH is distinctly mild, especially in girls and women, posing challenges for its recognition and management.
This article is protected by copyright. All rights reserved.
Ezh2 ameliorates osteoarthritis by activating TNFSF13B
07-01-2020 – Xiaotian Du, Yishan Chen, Qin Zhang, Junxin Lin, Yeke Yu, Zongyou Pan, Heng Sun, Chunhui Yuan, Dongsheng Yu, Haoyu Wu, Xiaoan Zhang, Jun Dai, Shouan Zhu, Yiting Zhou, Hongwei Ouyang
ABSTRACTEpigenetic regulation is highly correlated with osteoarthritis (OA) development, while the role and detailed mechanisms of it remain elusive. In this study, we explored the expression of EZH2, an H3K27me3 transferase, in human OA cartilages and its roles in regulating OA pathogenesis. Here, we found EZH2 was highly expressed in both mice and human OA cartilage samples by using histological analysis and RNA‐Sequencing. And medial meniscectomy (MMx) OA model results indicated the conditional knockout of Ezh2 deteriorated OA pathological conditions. Furthermore, we demonstrated the positive roles of Ezh2 in cartilage wound healing and inhibition of hypertrophy through activating TNFSF13B, a member of tumor necrosis factor superfamily. Further, we also indicated that the effect of TNFSF13B, increased by Ezh2, might boost the healing of chondrocytes through increasing the phosphorylation of Akt. Taken together, our results argue that An EZH2‐positive subpopulation was existed in OA patients and EZH2‐TNFSF13B signaling was responsible for regulating chondrocyte healing and hypertrophy. Thus, it might act as a new potential target for OA diagnosis and treatment.
This article is protected by copyright. All rights reserved.
Apoptotic osteocytes induce RANKL production in bystanders via purinergic signaling and activation of pannexin channels
07-01-2020 – Sean McCutcheon, Robert J. Majeska, David C. Spray, Mitchell B. Schaffler, Maribel Vazquez
Localized apoptosis of osteocytes, the tissue‐resident cells within bone, occurs with fatigue microdamage and activates bone resorption. Osteoclasts appear to target and remove dying osteocytes, resorbing damaged bone matrix as well. Osteocyte apoptosis similarly activates bone resorption with estrogen loss and in disuse. Apoptotic osteocytes trigger viable neighbor (i.e., Bystander) osteocytes to produce RANKL, the cytokine required for osteoclast activation. Signals from apoptotic osteocytes that trigger this bystander RANKL expression remain obscure. Studying signaling among osteocytes has been hampered by lack of in vitro systems that model the limited communication among osteocytes in vivo (i.e., via gap junctions on cell processes and/or paracrine signals through thin pericellular fluid spaces around osteocytes). Here, we used a novel multiscale fluidic device (the Macro‐micro‐nano, or Mμn) that reproduces these key anatomical features. Osteocytes in discrete compartments of the device communicate only via these limited pathways, which allows assessment of their roles in triggering osteocytes RANKL expression. Apoptosis of MLOY‐4 osteocytes in the Mμn device caused increased osteocyte RANKL expression in the neighboring compartment, consistent with in vivo findings. This RANKL upregulation in bystander osteocytes was prevented by blocking Pannexin 1 channels as well as its ATP receptor. ATP alone caused comparable RANKL upregulation in bystander osteocytes. Finally, blocking Connexin 43 gap junctions did not abolish osteocyte RANKL upregulation, but did alter the distribution of RANKL expressing bystander osteocytes. These findings point to extracellular ATP, released from apoptotic osteocytes via Panx1 channels, as a major signal for triggering bystander osteocyte RANKL expression and activating bone remodeling.
This article is protected by copyright. All rights reserved.
The Importance and Possible Clinical Impact of Measuring Trabecular and Cortical Bone Microstructure to Improve Fracture Risk Prediction
07-01-2020 – Mattias Lorentzon
Loss‐of‐Function Mutations in the ALPL Gene Presenting with Adult Onset Osteoporosis and Low Serum Concentrations of Total Alkaline Phosphatase
07-01-2020 – Nerea Alonso, Beatriz Larraz‐Prieto, Kathryn Berg, Zoe Lambert, Paul Redmond, Sarah E Harris, Ian J Deary, Carys Pugh, James Prendergast, Stuart H Ralston
ABSTRACTHypophosphatasia (HPP) is a rare inherited disorder characterized by rickets and low circulating concentrations of total alkaline phosphatase (ALP) caused by mutations in ALPL. Severe HPP presents in childhood but milder forms can present in adulthood. The prevalence and clinical features of adult HPP are poorly defined. The aim of this study was to evaluate the prevalence and clinical significance of low serum total alkaline phosphatase (ALP) levels in a clinic‐based population of adult osteoporotic patients. We searched for patients with low ALP in a cohort of 3285 patients referred to an osteoporosis clinic over a 10‐year period and performed mutation screening of ALPL in those with low ALP (≤40 U/L) on two or more occasions. These individuals were matched with four clinic controls with a normal ALP. We also evaluated the prevalence of low ALP and ALPL mutations in 639 individuals from the general population from the same region. We identified 16/3285 (0.49%) clinic patients with low ALP and 14 (87.5%) had potentially pathogenic variants in ALPL. Eight of these individuals were heterozygous for mutations previously described in HPP and 2 were heterozygous for novel mutations (p.
Arg301Trp and p.
Tyr101X). These mutations were not found in clinic controls or in the general population. Eight patients with low ALP, including 4 with ALPL mutations, were treated with bisphosphonates for an average of 6.5 years. In these individuals, the rate of fractures during treatment was comparable to that in normal ALP clinic controls who were treated with bisphosphonates. We conclude that heterozygous loss‐of‐function mutations in ALPL are common in osteoporosis patients with low ALP. Further studies are required to determine how best these individuals should be treated. © 2019 The Authors. Journal of Bone and Mineral Research published by American Society for Bone and Mineral Research.
PARP1 Hinders Histone H2B Occupancy at the NFATc1 Promoter to Restrain Osteoclast Differentiation
07-01-2020 – Chun Wang, Jianqiu Xiao, Kathrin Nowak, Kapila Gunasekera, Yael Alippe, Sheree Speckman, Tong Yang, Dustin Kress, Yousef Abu‐Amer, Michael O. Hottiger, Gabriel Mbalaviele
ABSTRACTInduction of nuclear factor of activated T cell cytoplasmic 1 (NFATc1) by macrophage colony‐stimulating factor (M‐CSF) and receptor activator of NF‐κB ligand (RANKL) is essential for macrophage differentiation into osteoclasts (OCs), but the underlying mechanisms remain unclear. The ability of poly(ADP‐ribose) polymerase 1 (PARP1) to poly‐ADP‐ribosylate NFATc1 in T cells prompted us to investigate the PARP1 and NFATc1 interaction during osteoclastogenesis. However, extensive studies failed to directly link PARP1 to NFATc1. A combination of transcriptomics and proteomics studies was then used to identify PARP1 targets under these conditions. These unbiased approaches in conjunction with site‐directed mutagenesis studies revealed that PARP1 inhibited NFATc1 expression and OC formation by ADP‐ribosylating histone H2B at serine 7 and decreasing the occupancy of this histone variant at the NFATc1 promoter. The anti‐osteoclastogenic function of PARP1 was confirmed in vivo in several mouse models of PARP1 loss‐of‐function or gain‐of‐function, including a novel model in which PARP1 was conditionally ablated in myeloid cells. Thus, PARP1 ADP‐ribosylates H2B to negatively regulate NFATc1 expression and OC differentiation. © 2019 American Society for Bone and Mineral Research.
LIGHT/TNFSF14 Promotes Osteolytic Bone Metastases in Non‐small Cell Lung Cancer Patients
07-01-2020 – Giacomina Brunetti, Dimas C Belisario, Sara Bortolotti, Giuseppina Storlino, Graziana Colaianni, Maria F Faienza, Lorenzo Sanesi, Valentina Alliod, Lucio Buffoni, Elisa Centini, Claudia Voena, Roberta Pulito, Silvia Novello, Giuseppe Ingravallo, Rita Rizzi, Giorgio Mori, Janne E Reseland, Carl F Ware, Silvia Colucci, Riccardo Ferracini, Maria Grano, Ilaria Roato
ABSTRACTTumor necrosis factor superfamily member 14 (TNFSF14), LIGHT, is a component of the cytokine network that regulates innate and adaptive immune responses, which promote homeostasis of lymphoid organs, liver, and bone. Metastatic tumors often disrupt the tissue microenvironment, thus altering the homeostasis of the invaded organ; however, the underlying mechanisms required further studies. We investigated the role of LIGHT in osteolytic bone disease induced by metastatic non‐small cell lung cancer (NSCLC). Patients diagnosed with NSCLC bone metastasis show significantly higher levels of LIGHT expressed in monocytes compared with non‐bone metastatic tumors and healthy controls. Serum LIGHT levels were also higher in patients with bone metastases than in controls, suggesting a role for LIGHT in stimulating osteoclast precursors. In bone metastatic patients, we also detected increased RNA expression and serum RANKL levels, thus by adding anti‐LIGHT or RANK–fragment crystallizable region (RANK‐Fc) in PBMC cultures, a significant inhibition of osteoclastogenesis was observed. To model this observation in mice, we used the mouse lung cancer cell line LLC‐1. After intratibial implantation, wild‐type mice showed an increased number of osteoclasts but reduced numbers of osteoblasts and decreased osteoid formation. In contrast, Tnfsf14−/− mice showed no significant bone loss or other changes in bone homeostasis associated with this model. These data indicate LIGHT is a key control mechanism for regulating bone homeostasis during metastatic invasion. Thus, LIGHT may be a novel therapeutic target in osteolytic bone metastases. © 2019 American Society for Bone and Mineral Research.
Genetically Decreased Circulating Vascular Endothelial Growth Factor and Osteoporosis Outcomes: A Mendelian Randomization Study
06-01-2020 – Julyan Keller‐Baruch, Vincenzo Forgetta, Despoina Manousaki, Sirui Zhou, J Brent Richards
ABSTRACTVascular endothelial growth factor (VEGF) is important for bone formation and has been associated with osteoporosis in humans. Therefore, we conducted a two‐sample Mendelian randomization study to test whether genetically decreased circulating VEGF was associated with decreased bone mineral density (BMD) and increased risk of fracture. Summary statistics from a genomewide association study (GWAS) meta‐analysis of circulating VEGF level (n = 16,112) were used to identify 10 genetic variants explaining up to 52% of the variance in circulating VEGF levels. GWAS meta‐analyses on dual‐energy X‐ray absorptiometry (DXA)‐derived BMD of forearm, lumbar spine, and femoral neck (n = up to 32,735) and BMD estimated from heel calcaneus ultrasound (e
BMD) (n = 426,824) were used to assess the effect of genetically lowered circulating VEGF levels on BMD. A GWAS meta‐analysis including a total of 76,549 cases and 470,164 controls was used to assess the effect of genetically lowered circulating VEGF levels on risk of fracture. A natural log‐transformed pg/m
L decrease in circulating VEGF levels was not associated with a decrease in forearm BMD (0.02 standard deviation SD, 95% confidence interval CI −0.024 to 0.064, p = 0.38), lumbar spine BMD (−0.005 SD, 95% CI −0.03 to 0.019, p = 0.67), femoral neck BMD (0.004 SD, 95% CI −0.017 to 0.026, p = 0.68), e
BMD (−0.006 SD, 95% CI −0.012 to −0.001, p = 0.031) or risk of fracture (odds ratio = 0.99, 95% CI 0.98 to 1.0, p = 0.37) in inverse‐variance–weighted Mendelian randomization analyses. Sensitivity analyses did not provide evidence that our results were influenced by pleiotropy. Genetically lowered circulating VEGF was not associated with a decrease in BMD or increased risk of fracture, suggesting that efforts to influence circulating VEGF level are unlikely to have beneficial effects on osteoporosis outcomes and that previous observational associations of circulating VEGF with BMD were influenced by confounding or reverse causation. © 2019 American Society for Bone and Mineral Research.
Irisin Prevents Disuse‐Induced Osteocyte Apoptosis
06-01-2020 – Giuseppina Storlino, Graziana Colaianni, Lorenzo Sanesi, Luciana Lippo, Giacomina Brunetti, Mariella Errede, Silvia Colucci, Giovanni Passeri, Maria Grano
Schematic representation of irisins action on osteocytes to activate ERK phosphorylation, which in turn stimulates the increase of Atf4 m
RNA levels. A recent study showed that irisin increases survival of osteocytes acting through integrin αV/β5 receptors. To elucidate the action of irisin on osteocytes, we investigated the downstream signaling cascades in MLO‐Y4 cells treated with recombinant irisin (rec‐irisin). We found that rec‐irisin activated the MAP kinases Erk1 and Erk2 and increased the expression of the transcription factor Atf4 through an Erk‐dependent pathway in osteocytes.
ABSTRACTPrevious results showed that intermittently administered irisin improves bone mass in normal mice and prevents the development of disuse‐induced osteoporosis and muscular atrophy in hindlimb‐suspended mice, a murine model able to mimic the absence of mechanical loading. A recent study showed that irisin increases survival of osteocytes acting through integrin αV/β5 receptors. To better understand the action of irisin on these cells, we investigated the downstream signaling cascades in osteocyte‐like cells (MLO‐Y4) treated with recombinant irisin (rec‐irisin) in vitro and we analyzed survival of osteocytes and caspase activation in cortical bone of osteoporotic mice treated with rec‐irisin in vivo. Our results revealed that rec‐irisin activated the MAP kinases Erk1 and Erk2 and increased the expression of the transcription factor Atf4 (2.5‐fold, p < .05) through an Erk‐dependent pathway in osteocytes. Some key genes expressed by MLO‐Y4 cells were modulated by long‐term irisin treatment, either continuously administered or given with intermittent short pulses. Interestingly, Sost m
RNA was severely downregulated only upon intermittent irisin administration (10‐fold, p < .001). Furthermore, rec‐irisin upregulated Tfam m
RNA (fourfold, p < .05) and Bcl2/Bax ratio (twofold, p < .05) in MLO‐Y4 cells. By detecting caspase‐9 and caspase‐3, we also found that rec‐irisin inhibited apoptosis induced by hydrogen peroxide and dexamethasone, respectively. In cortical bone of unloading C57BL6 mice treated with vehicle (unload‐veh), irisin prevented disuse‐induced reduction of viable osteocytes (+30% versus unload‐veh, p < .05) and increase of empty lacunae (+110% versus unload‐veh, p < .05), as well as caspase‐9 (threefold, p < .05) and caspase‐3 (twofold, p < .05) activations. Our findings revealed underlying mechanisms of irisin action on osteocytes, which increases their functions and exerts anti‐apoptotic effects, confirming that mechanosensor cells of bone are sensitive to the exercise‐mimetic myokine irisin. © 2019 American Society for Bone and Mineral Research.
Differential Effect of Long‐Term Systemic Exposure of TNFα on Health of the Annulus Fibrosus and Nucleus Pulposus of the Intervertebral Disc
06-01-2020 – Deborah J Gorth, Olivia K Ottone, Irving M Shapiro, Makarand V Risbud
ABSTRACTThe inflammatory cytokine tumor necrosis factor alpha (TNFα) is considered to play a key role in the pathogenesis of intervertebral disc disease. To evaluate the importance of this cytokine we examined the inflammatory environment and spinal phenotype of 9‐month‐old human TNFα overexpressing transgenic (h
TNFα‐TG) mice. The mice evidenced increased circulating levels of interleukin‐1β (IL‐1β), IL‐2, keratinocyte chemoattractant/human growth‐regulated oncogene (KC/GRO), and monocyte chemoattractant protein‐1 (MCP‐1) along with thinning of the cortical and trabecular vertebral bone. Surprisingly, although the nucleus pulposus (NP) of these mice was intact and healthy, the caudal annulus fibrosus (AF) evidenced robust cell death and immune cell infiltration. Despite these differences, there were no obvious alterations in the collagen or aggrecan content in the NP and AF. However, there was a reduction in cartilage oligomeric matrix protein (COMP), suggesting destabilization of the AF matrix. Microarray analysis of the NP from h
TNFα‐TG mice cells revealed minimal changes in global gene expression. These findings lend support to the notion that NP tissue is isolated from systemic inflammation. In contrast, the severe AF phenotype suggests that systemic inflammation interferes with AF health, predisposing discs to herniation as opposed to directly causing NP degeneration. © 2020 American Society for Bone and Mineral Research.
Improved in vivo Experimental Screening Identifies an Anabolic Analog of 1,25 Dihydroxyvitamin D3 With Minimal Bone Resorption Activity
06-01-2020 – Laura M Calvi
Inhibition of Osteoclastogenesis by the RNA‐Binding Protein QKI5: a Novel Approach to Protect from Bone Resorption
31-12-2019 – Benjamin Rauwel, Yannick Degboé, Katy Diallo, Souraya Sayegh, Michel Baron, Jean‐Frédéric Boyer, Arnaud Constantin, Alain Cantagrel, Jean‐Luc Davignon
HCMV infection inhibits osteoclastogenesis through a mechanism involving RNA binding protein QKI5. Overexpression of QKI5 protects from bone degradation and could be a new therapeutic target to limit bone erosion during osteoclast‐related diseases.
ABSTRACTIncreased osteoclastogenesis is a common feature of bone erosion, notably in osteoporosis but also in inflammatory diseases such as rheumatoid arthritis (RA) and osteoarticular infections. Human cytomegalovirus (HCMV) infection has been described to impair monocyte differentiation into macrophages and dendritic cells. However, its effect on monocyte‐derived osteoclasts is yet to be determined. We showed here that in vitro HCMV infection is associated with an inhibition of osteoclastogenesis through decreased expression of colony stimulating factor 1 receptor (CSF‐1R) and RANK in monocytes, which was mediated by an upregulation of quaking I‐5 protein (QKI‐5), a cellular RNA‐interacting protein. We found that deliberate QKI5 overexpression in the absence of HCMV infection is able to decrease CSF‐1R and RANK expression, leading to osteoclastogenesis inhibition. Finally, by using lentiviral vectors in a calvarial bone erosion mouse model, we showed that QKI5 inhibits bone degradation. This work identifies QKI5 as a strong inhibitor of bone resorption. Future research will point out whether QKI5 could be a target for bone pathologies. © 2020 American Society for Bone and Mineral Research.
Oral Iron for Prevention and Treatment of Rickets and Osteomalacia in Autosomal Dominant Hypophosphatemia
31-12-2019 – Wolfgang Högler, Klaus Kapelari
ABSTRACTAutosomal dominant hypophosphatemia (ADH) causes rickets, osteomalacia, and taurodontism due to heterozygous mutations in FGF23, which inhibit the inactivation (cleavage) of the encoded protein, the hormone fibroblast growth factor 23 (FGF23). Iron deficiency increases FGF23 m
RNA expression and recent evidence suggests that the recurrent, late‐onset, or waxing‐waning hypophosphatemic phenotype may be linked to synchronous variations in iron status. The fact that most adult symptomatic ADH patients are females during reproductive age supports the notion of a gene‐environmental interaction. Practically all symptomatic hypophosphatemic patients described in the recent literature were also iron deficient (with/without anemia) at presentation, when measured. Given its interaction with FGF23, correcting iron deficiency should therefore also correct FGF23 excess. Following the original report of successful phenotype reversal in an iron‐deficient ADH child using oral iron supplementation in 2015, more evidence has emerged that supports the use of the element iron to restore homoeostasis of the element phosphorus (in addition to its own). We put into perspective the recent evidence and add 14 years observational data on the original case that demonstrates the correlation of serum phosphorus and renal tubular phosphate reabsorption in mass per unit volume of glomerular filtrate (Tm
P/GFR) with serum ferritin. Presentation and relapse of ADH, 12 years apart, occurred during iron deficiency, and the onset of menstrual periods was associated with relapse. Here we propose management guidance for patients affected by ADH throughout the lifespan based on iron stores. Because ferritin correlates best with hypophosphatemia historically, and in long‐term observation of the originally treated case, it should be used as the monitoring tool and kept in the normal range. Women with ADH who are of reproductive age and other risk groups require supplementation with oral iron using WHO guidelines. Treatment of this form of FGF23 excess may not require phosphate and active vitamin D, or burosumab. © 2020 American Society for Bone and Mineral Research
Heterogeneous Spatial and Strength Adaptation of the Proximal Femur to Physical Activity: A Within‐Subject Controlled Cross‐Sectional Study
30-12-2019 – Stuart J Warden, Julio Carballido‐Gamio, Alyssa M Weatherholt, Joyce H Keyak, Chenxi Yan, Mariana E Kersh, Thomas F Lang, Robyn K Fuchs
ABSTRACTPhysical activity (PA) enhances proximal femur bone mass, as assessed using projectional imaging techniques. However, these techniques average data over large volumes, obscuring spatially heterogeneous adaptations. The current study used quantitative computed tomography, statistical parameter mapping, and subject‐specific finite element (FE) modeling to explore spatial adaptation of the proximal femur to PA. In particular, we were interested in adaptation occurring at the superior femoral neck and improving strength under loading from a fall onto the greater trochanter. High/long jump athletes (n = 16) and baseball pitchers (n = 16) were utilized as within‐subject controlled models as they preferentially load their take‐off leg and leg contralateral to their throwing arm, respectively. Controls (n = 15) were included but did not show any dominant‐to‐nondominant (D‐to‐ND) leg differences. Jumping athletes showed some D‐to‐ND leg differences but less than pitchers. Pitchers had 5.8% (95% confidence interval CI 3.9%–7.6%) D‐to‐ND leg differences in total hip volumetric bone mineral density (v
BMD), with increased v
BMD in the cortical compartment of the femoral neck and trochanteric cortical and trabecular compartments. Voxel‐based morphometry analyses and cortical bone mapping showed pitchers had D‐to‐ND leg differences within the regions of the primary compressive trabeculae, inferior femoral neck, and greater trochanter but not the superior femoral neck. FE modeling revealed pitchers had 4.1% (95% CI 1.4%–6.7%) D‐to‐ND leg differences in ultimate strength under single‐leg stance loading but no differences in ultimate strength to a fall onto the greater trochanter. These data indicate the asymmetrical loading associated with baseball pitching induces proximal femur adaptation in regions associated with weight bearing and muscle contractile forces and increases strength under single‐leg stance loading. However, there were no benefits evident at the superior femoral neck and no measurable improvement in ultimate strength to common injurious loading during aging (ie, fall onto the greater trochanter), raising questions as to how to better target these variables with PA. © 2019 American Society for Bone and Mineral Research.
Increased Expression of FGF‐21 Negatively Affects Bone Homeostasis in Dystrophin/Utrophin Double Knockout Mice
30-12-2019 – Hongshuai Li, Hui Sun, Baoli Qian, Wei Feng, Dwayne Carney, Jennifer Miller, MaCalus V Hogan, Ling Wang
ABSTRACTDuchenne muscular dystrophy (DMD) is the most common muscular dystrophy seen in children. In addition to skeletal muscle, DMD also has a significant impact on bone. The pathogenesis of bone abnormalities in DMD is still unknown. Recently, we have identified a novel bone‐regulating cytokine, fibroblast growth factor‐21 (FGF‐21), which is dramatically upregulated in skeletal muscles from DMD animal models. We hypothesize that muscle‐derived FGF‐21 negatively affects bone homeostasis in DMD. Dystrophin/utrophin double‐knockout (d
KO) mice were used in this study. We found that the levels of circulating FGF‐21 were significantly higher in d
KO mice than in age‐matched WT controls. Further tests on FGF‐21 expressing tissues revealed that both FGF‐21 m
RNA and protein expression were dramatically upregulated in dystrophic skeletal muscles, whereas FGF‐21 m
RNA expression was downregulated in liver and white adipose tissue (WAT) compared to WT controls. Neutralization of circulating FGF‐21 by i.p. injection of anti‐FGF‐21 antibody significantly alleviated progressive bone loss in weight‐bearing (vertebra, femur, and tibia) and non–weight bearing bones (parietal bones) in d
KO mice. We also found that FGF‐21 directly promoted RANKL‐induced osteoclastogenesis from bone marrow macrophages (BMMs), as well as promoted adipogenesis while concomitantly inhibiting osteogenesis of bone marrow mesenchymal stem cells (BMMSCs). Furthermore, fibroblast growth factor receptors (FGFRs) and co‐receptor β‐klotho (KLB) were expressed in bone cells (BMM‐derived osteoclasts and BMMSCs) and bone tissues. KLB knockdown by small interfering RNAs (si
RNAs) significantly inhibited the effects of FGF21 on osteoclast formation of BMMs and on adipogenic differentiation of BMMSCs, indicating that FGF‐21 may directly affect dystrophic bone via the FGFRs‐β‐klotho complex. In conclusion, this study shows that dystrophic skeletal muscles express and secrete significant levels of FGF‐21, which negatively regulates bone homeostasis and represents an important pathological factor for the development of bone abnormalities in DMD. The current study highlights the importance of muscle/bone cross‐talk via muscle‐derived factors (myokines) in the pathogenesis of bone abnormalities in DMD. © 2019 American Society for Bone and Mineral Research.
Direct Reprogramming of Mouse Fibroblasts into Functional Osteoblasts
30-12-2019 – Hui Zhu, Srilatha Swami, Pinglin Yang, Frederic Shapiro, Joy Y. Wu
ABSTRACTAlthough induced pluripotent stem cells hold promise as a potential source of osteoblasts for skeletal regeneration, the induction of pluripotency followed by directed differentiation into osteoblasts is time consuming and low yield. In contrast, direct lineage reprogramming without an intervening stem/progenitor cell stage would be a more efficient approach to generate osteoblasts. We screened combinations of osteogenic transcription factors and identified four factors, Runx2, Osx, Dlx5, and ATF4, that rapidly and efficiently reprogram mouse fibroblasts derived from 2.3 kb type I collagen promoter‐driven green fluorescent protein (Col2.3GFP) transgenic mice into induced osteoblast cells (i
OBs exhibit osteoblast morphology, form mineralized nodules, and express Col2.3GFP and gene markers of osteoblast differentiation. The global transcriptome profiles validated that i
OBs resemble primary osteoblasts. Genomewide DNA methylation analysis demonstrates that within differentially methylated loci, the methylation status of i
OBs more closely resembles primary osteoblasts than mouse fibroblasts. We further demonstrate that Col2.3GFP+ i
OBs have transcriptome profiles similar to GFP+ cells harvested from Col2.3GFP mouse bone chips. Functionally, Col2.3GFP+ i
OBs form mineralized bone structures after subcutaneous implantation in immunodeficient mice and contribute to bone healing in a tibia bone fracture model. These findings provide an approach to derive and study osteoblasts for skeletal regeneration. © 2019 American Society for Bone and Mineral Research.
Risk Factors of Severe Hypocalcemia After US‐Guided Percutaneous Microwave Ablation of the Parathyroid Gland in Patients with Secondary Hyperparathyroidism
30-12-2019 – Ying Wei, Li‐li Peng, Zhen‐long Zhao, Yan Li, Ming‐an Yu
ABSTRACTOur aim was to identify potential risk factors associated with severe hypocalcemia (SH) after microwave ablation (MWA) in patients with secondary hyperparathyroidism (SHPT). This retrospective cross‐sectional study enrolled 204 consecutive patients (with 387 parathyroid glands) who underwent MWA between July 2015 and May 2018. Clinical parameters, laboratory indices, and parathyroid gland characteristics were analyzed to assess risk factors associated with SH after MWA. SH was defined as serum calcium level lower than 1.875 mmol/L (7.5 mg/d
L) after MWA. Two models (I and II) for pre‐MWA and post‐MWA prediction were established, respectively. In accordance with the KDIGO guidelines, the target value for intact parathyroid hormone (i
PTH) less than 300 pg/m
L within 7 days after MWA was considered as a successful procedure. The success rate of MWA was 71.6% (146/204). The incidence of hypocalcemia and SH after MWA was 35.8% and 22.06%, respectively. The pre‐MWA prediction models I and II showed that high pre‐MWA i
PTH, a dramatic reduction in i
PTH, low pre‐MWA serum calcium, multiple ablated gland, and lack of pruritus symptoms were risk factors for developing SH. The accuracy (82.23% versus 83.25% in models I and II, respectively), sensitivity (34.88% versus 44.19%), specificity (95.45% versus 94.59%), positive predictive value (PPV) (68.18% versus 70.37%), and negative predictive value (NPV) (84% versus 85.37%) of both models were promising. The logistic regression fitting of the nomograms showed high prediction efficiency (0.845 and 0.863). High pre‐MWA i
PTH, dramatic reductions in i
PTH, low pre‐MWA serum calcium, multiple gland ablation, and no pruritus symptoms were predictors of SH. © 2019 American Society for Bone and Mineral Research.
Effect of Advanced Glycation End‐Products (AGE) Lowering Drug ALT‐711 on Biochemical, Vascular, and Bone Parameters in a Rat Model of CKD‐MBD
30-12-2019 – “Neal X Chen, Shruthi Srinivasan, Kalisha ONeill, Thomas L Nickolas, Joseph M Wallace, Matthew R Allen, Corinne E Metzger, Amy Creecy, Keith G Avin, Sharon M Moe”
ABSTRACTChronic kidney disease–mineral bone disorder (CKD‐MBD) is a systemic disorder that affects blood measures of bone and mineral homeostasis, vascular calcification, and bone. We hypothesized that the accumulation of advanced glycation end‐products (AGEs) in CKD may be responsible for the vascular and bone pathologies via alteration of collagen. We treated a naturally occurring model of CKD‐MBD, the Cy/+ rat, with a normal and high dose of the AGE crosslink breaker alagebrium (ALT‐711), or with calcium in the drinking water to mimic calcium phosphate binders for 10 weeks. These animals were compared to normal (NL) untreated animals. The results showed that CKD animals, compared to normal animals, had elevated blood urea nitrogen (BUN), PTH, FGF23 and phosphorus. Treatment with ALT‐711 had no effect on kidney function or PTH, but 3 mg/kg lowered FGF23 whereas calcium lowered PTH. Vascular calcification of the aorta assessed biochemically was increased in CKD animals compared to NL, and decreased by the normal, but not high dose of ALT‐711, with parallel decreases in left ventricular hypertrophy. ALT‐711 (3 mg/kg) did not alter aorta AGE content, but reduced aorta expression of receptor for advanced glycation end products (RAGE) and NADPH oxidase 2 (NOX2), suggesting effects related to decreased oxidative stress at the cellular level. The elevated total bone AGE was decreased by 3 mg/kg ALT‐711 and both bone AGE and cortical porosity were decreased by calcium treatment, but only calcium improved bone properties. In summary, treatment of CKD‐MBD with an AGE breaker ALT‐711, decreased FGF23, reduced aorta calcification, and reduced total bone AGE without improvement of bone mechanics. These results suggest little effect of ALT‐711 on collagen, but potential cellular effects. The data also highlights the need to better measure specific types of AGE proteins at the tissue level in order to fully elucidate the impact of AGEs on CKD‐MBD. © 2019 American Society for Bone and Mineral Research.
Myeloma cells down‐regulate adiponectin in bone marrow adipocytes via TNF‐alpha
30-12-2019 – Emma V. Morris, Karla J. Suchacki, Joseph Hocking, Rachel Cartwright, Aneka Sowman, Beatriz Gamez, Ryan Lea, Matthew T. Drake, William P. Cawthorn, Claire M. Edwards
Multiple myeloma is caused by abnormal plasma cells that accumulate in the bone marrow and interact with resident cells of the bone microenvironment to drive disease progression and development of an osteolytic bone disease. Bone marrow adipocytes (BMAds) are emerging as having important endocrine functions that can support myeloma cell growth and survival. However, how BMAds respond to infiltrating tumour cells remains poorly understood. Using the C57BL/Ka
Rij murine model of myeloma, bone marrow adiposity was found to be increased in early stage myeloma with BMAds localising along the tumour‐bone interface at later stages of disease. Myeloma cells were found to uptake BMAd‐derived lipids in vitro and in vivo although, lipid uptake was not associated with the ability of BMAds to promote myeloma cell growth and survival. However, BMAd‐derived factors were found to increase myeloma cell migration, viability and the evasion of apoptosis. BMAds are a major source of adiponectin, which is known to be myeloma‐suppressive. Myeloma cells were found to down‐regulate adiponectin specifically in a model of BMAds, but not in white adipocytes. The ability of myeloma cells to down‐regulate adiponectin was dependent at least in part on tumour‐derived TNF‐alpha. Collectively our data support the link between increased bone marrow adiposity and myeloma progression. By demonstrating how myeloma cells release TNF‐alpha to down‐regulate BMAd‐derived adiponectin, we reveal a new mechanism by which myeloma cells alter the bone microenvironment to support disease progression.
This article is protected by copyright. All rights reserved.
Heterogeneity and Spatial Distribution of Intravertebral Trabecular Bone Mineral Density in the Lumbar Spine is Associated with Prevalent Vertebral Fracture
30-12-2019 – Jarred Kaiser, Brett Allaire, Paul M Fein, Darlene Lu, Alexander Adams, Douglas P. Kiel, Mohamed Jarraya, Ali Guermazi, Serkalem Demissie, Elizabeth J. Samelson, Mary L. Bouxsein, Elise F Morgan
The spatial heterogeneity in trabecular bone density within the vertebral centrum is associated with vertebral strength and could explain why volumetric bone mineral density (v
BMD) exhibits low sensitivity in identifying fracture risk. This study evaluated whether the heterogeneity and spatial distribution of trabecular v
BMD are associated with prevalent vertebral fracture.
We examined the volumetric QCT scans of the L3 vertebra in 148 participants in the Framingham Heart Study Multidetector CT study. Of these individuals, 37 were identified as cases of prevalent fracture, and 111 were controls, matched on sex and age with three controls per case. v
BMD was calculated within 5‐mm contiguous cubic regions of the centrum. Two measures of heterogeneity were calculated: 1) interquartile range (IQR); and 2) quartile coefficient of variation (QCV). Spatial distributions of the trabecular v
BMD were also calculated: anterior/posterior, central/outer, superior/mid‐transverse, and inferior/mid‐transverse. Heterogeneity and spatial distributions were compared between cases and controls using Wilcoxon Rank Sum tests and t‐tests and tested for association with prevalent fractures with conditional logistic regressions independent of integral v
Prevalent fracture cases had lower mean (SD) integral v
BMD (134 (38) vs.165 (42) mg/cm3, p<0.001), higher QCV (0.22 (0.13) vs. 0.17 (0.09), p=0.003), and lower anterior/posterior r
BMD (0.65 (0.13) vs 0.78 (0.16), p<0.001) than controls. QCV was positively associated with increased odds of prevalent fracture (OR=1.61; 95% CI: 1.04‐2.49, p=0.034), but this association was not independent of integral v
BMD (p=0.598). Increased anterior/posterior trabecular v
BMD ratio was associated with decreased odds of prevalent fracture independent of integral v
BMD (OR= 0.38; 95% CI: 0.20‐0.71, p=0.003).
In conclusion, increased trabecular v
BMD in the anterior vs. posterior centrum, but not trabecular v
BMD heterogeneity, was associated with decreased risk of prevalent fracture independent of integral v
BMD. Regional measurements of trabecular v
BMD could aid in determining the risk and underlying mechanisms of vertebral fracture.
This article is protected by copyright. All rights reserved.
Involvement of the gut microbiota and barrier function in glucocorticoid induced osteoporosis
30-12-2019 – Jonathan D Schepper, Fraser Collins, Naiomy Deliz Rios‐Arce, Ho Jun Kang, Laura Schaefer, Joseph D. Gardinier, Ruma Raghuvanshi, Robert A. Quinn, Robert Britton, Narayanan Parameswaran, Laura R McCabe
Glucocorticoids (GCs) are potent immune‐modulating drugs with significant side effects, including glucocorticoid‐induced osteoporosis (GIO). GCs directly induce osteoblast and osteocyte apoptosis but also alter intestinal microbiota composition. While the gut microbiota is known to contribute to the regulation of bone density, its role in GIO has never been examined. To test this, male C57/Bl6J mice were treated 8‐weeks with GC (prednisolone, GC‐Tx) in the presence or absence of broad‐spectrum antibiotic treatment (ABX) to deplete the microbiota. Long‐term ABX prevented GC‐Tx‐induced trabecular bone loss, demonstrating the requirement of gut microbiota for GIO. Treatment of GC‐Tx mice with a probiotic (Lactobacillus reuteri, LR) prevented trabecular bone loss. Microbiota analyses indicated that GC‐Tx changed the abundance of Verrucomicobiales and Bacteriodales phylums and random forest analyses indicated significant differences in abundance of Porphyromonadaceae and Clostridiales OTUs between groups. Furthermore, transplantation of GC‐Tx mouse fecal material into recipient naïve, untreated WT mice caused bone loss, supporting a functional role for microbiota in GIO. We also report that GC caused intestinal barrier breaks, as evidence by increased serum endotoxin level (2.4‐fold), that were prevented by LR and ABX treatments. Enhancement of barrier function with a mucus supplement prevented both GC‐Tx‐induced barrier leakage and trabecular GIO. In bone, treatment with ABX, LR or a mucus supplement reduced GC‐Tx‐induced osteoblast and osteocyte apoptosis. GC‐Tx suppression of Wnt10b in bone was restored by the LR and MDY treatments as well as microbiota depletion. Finally, we identified that bone‐specific Wnt10b overexpression prevented GIO. Taken together, our data highlight the previously unappreciated involvement of the gut microbiota and intestinal barrier function in trabecular GIO pathogenesis (including Wnt10b suppression and osteoblast and osteocyte apoptosis) and identify the gut as a novel therapeutic target for preventing GIO.
This article is protected by copyright. All rights reserved.
Disorder of iron metabolism inhibits the recovery of unloading‐induced bone loss in hypomagnetic field
27-12-2019 – Yanru Xue, Jiancheng Yang, Jie Luo, Li Ren, Ying Shen, Dandan Dong, Yanwen Fang, Lijiang Hu, Mengyu Liu, Zhongcai Liao, Jun Li, Zhicai Fang, Peng Shang
Exposure of humans and animals to microgravity in spaceflight results in variously deleterious effects on bone health. In addition to microgravity, the hypomagnetic field (Hy
MF) also is an extreme environment in space, such as on the Moon and Mars, magnetic intensity is far weaker than the geomagnetic field (GMF) on the earth. Recently, we demonstrated that Hy
MF promoted additional bone loss in hindlimb unloading‐induced bone loss, and the underlying mechanism probably involved in the increase of body iron storage. Numerous studies have indicated that bone loss induced by mechanical unloading can be largely restored after skeletal reloading in GMF condition. However, it is unknown whether this bone deficit can return to a healthy state under Hy
MF condition. Therefore, the purpose of this study is to examine the effects of Hy
MF on the recovery of microgravity‐induced bone loss, and illustrates the changes of body iron storage in this process. Our results demonstrated that there was lower bone mineral content (BMC) in the Hy
MF reloading group compared to the GMF reloading group. Reloaded mice in the Hy
MF condition had a worse microstructure of femur than in the GMF condition. Femoral mechanical properties, including the elastic modulus, stiffness, and ultimate stress were poorer and toughness was higher in the Hy
MF group compared with the GMF group. Simultaneously, more iron content in serum, the tibia, liver and spleen were found under Hy
MF reloading than GMF reloading. The iron chelator deferoxamine mesylate (DFO) decreased the iron content in the bone, liver and spleen, and significantly relieved unloading‐induced bone loss under Hy
MF reloading. These results showed that Hy
MF inhibits the recovery of microgravity‐induced bone loss, probably by suppressing elevated iron levels return to physiological level.
This article is protected by copyright. All rights reserved.
Abaloparatide at the Same Dose Has the Same Effects on Bone as PTH (1‐34) in Mice
27-12-2019 – Carole Le Henaff, Florante Ricarte, Brandon Finnie, Zhiming He, Joshua Johnson, Johanna Warshaw, Victoria Kolupaeva, Nicola C Partridge
ABSTRACTAbaloparatide, a novel analog of parathyroid hormone‐related protein (PTHr
P 1–34), became in 2017 the second osteoanabolic therapy for the treatment of osteoporosis. This study aims to compare the effects of PTH (1‐34), PTHr
P (1‐36), and abaloparatide on bone remodeling in male mice. Intermittent daily subcutaneous injections of 80 μg/kg/d were administered to 4‐month‐old C57Bl/6J male mice for 6 weeks. During treatment, mice were followed by DXA‐Piximus to assess changes in bone mineral density (BMD) in the whole body, femur, and tibia. At either 4 or 18 hours after the final injection, femurs were harvested for μCT analyses and histomorphometry, sera were assayed for bone turnover marker levels, and tibias were separated into cortical, trabecular, and bone marrow fractions for gene expression analyses. Our results showed that, compared with PTH (1‐34), abaloparatide resulted in a similar increase in BMD at all sites, whereas no changes were found with PTHr
P (1‐36). With both PTH (1‐34) and abaloparatide, μCT and histomorphometry analyses revealed similar increases in bone volume associated with an increased trabecular thickness, in bone formation rate as shown by P1NP serum level and in vivo double labeling, and in bone resorption as shown by CTX levels and osteoclast number. Gene expression analyses of trabecular and cortical bone showed that PTH (1‐34) and abaloparatide led to different actions in osteoblast differentiation and activity, with increased Runx2, Col1A1, Alpl, Bsp, Ocn, Sost, Rankl/Opg, and c‐fos at different time points. Abaloparatide seems to generate a faster response on osteoblastic gene expression than PTH (1‐34). Taken together, abaloparatide at the same dose is as effective as PTH (1‐34) as an osteoanabolic, with an increase in bone formation but also an increase in bone resorption in male mice. © 2019 American Society for Bone and Mineral Research.
2019 Annual Meeting of the American Society for Bone and Mineral Research Orange County Convention Center, Orlando, Florida, USA September 20–23, 2019
The Polycomb Protein Bmi1 Plays a Crucial Role in the Prevention of 1,25(OH)2D Deficiency‐Induced Bone Loss
17-12-2019 – Haijian Sun, Wanxin Qiao, Min Cui, Cuicui Yang, Rong Wang, David Goltzman, Jianliang Jin, Dengshun Miao
ABSTRACTWe analyzed the skeletal phenotypes of heterozygous null Cyp27b1 (Cyp27b1+/−) mice and their wild‐type (WT) littermates to determine whether haploinsufficiency of Cyp27b1 accelerated bone loss, and to examine potential mechanisms of such loss. We found that serum 1,25‐dihydroxyvitamin D 1,25(OH)2D levels were significantly decreased in aging Cyp27b1+/− mice, which displayed an osteoporotic phenotype. This was accompanied by a reduction of expression of the B lymphoma Moloney murine leukemia virus (Mo‐MLV) insertion region 1 (Bmi1) at both gene and protein levels. Using chromatin immunoprecipitation (Ch
IP)‐PCR, electrophoretic mobility shift assay (EMSA) and a luciferase reporter assay, we then showed that 1,25(OH)2D3 upregulated Bmi1 expression at a transcriptional level via the vitamin D receptor (VDR). To determine whether Bmi1 overexpression in mesenchymal stem cells (MSCs) could correct bone loss induced by 1,25(OH)2D deficiency, we overexpressed Bmi1 in MSCs using Prx1‐driven Bmi1 transgenic mice (Bmi1Tg) mice. We then compared the bone phenotypes of Bmi1Tg mice on a Cyp27b1+/− background, with those of Cyp27b1+/− mice and with those of WT mice, all at 8 months of age. We found that overexpression of Bmi1 in MSCs corrected the bone phenotype of Cyp27b1+/− mice by increasing osteoblastic bone formation, reducing osteoclastic bone resorption, increasing bone volume, and increasing bone mineral density. Bmi1 overexpression in MSCs also corrected 1,25(OH)2D deficiency‐induced oxidative stress and DNA damage, and cellular senescence of Cyp27b1+/− mice by reducing levels of reactive oxygen species (ROS), elevating serum total superoxide dismutase levels, reducing the percentage of γH2A.
X, p16, IL‐1β, and TNF‐α–positive cells and decreasing γH2A.
X, p16, p19, p53, p21, IL‐1β, and IL‐6 expression levels. Furthermore, 1,25(OH)2D stimulated the osteogenic differentiation of MSCs, both ex vivo and in vitro, from WT mice but not from Bmi1−/− mice and 1,25(OH)2D administration in vivo increased osteoblastic bone formation in WT, but not in Bmi1 −/− mice. Our results indicate that Bmi1, a key downstream target of 1,25(OH)2D, plays a crucial role in preventing bone loss induced by 1,25(OH)2D deficiency. © 2019 American Society for Bone and Mineral Research.
The Accuracy of Prevalent Vertebral Fracture Detection in Children Using Targeted Case‐Finding Approaches
17-12-2019 – Jinhui Ma, Kerry Siminoski, Peiyao Wang, Nathalie Alos, Elizabeth A Cummings, Janusz Feber, Jacqueline Halton, Josephine Ho, Kristin Houghton, Bianca Lang, Paivi M Miettunen, Rosie Scuccimarri, Jacob L Jaremko, Khaldoun Koujok, Brian Lentle, Mary Ann Matzinger, Nazih Shenouda, Frank Rauch, Leanne M Ward, and the Canadian Steroid‐Induced Osteoporosis in the Pediatric Population (STOPP) Consortium
ABSTRACTDue to concerns about cumulative radiation exposure in the pediatric population, it is not standard practice to perform spine radiographs in most conditions that predispose to vertebral fracture (VF). In this study we examined the accuracy of two clinical predictors, back pain and lumbar spine bone mineral density (LS BMD), to derive four case‐finding paradigms for detection of prevalent VF (PVF). Subjects were 400 children at risk for PVF (leukemia 186, rheumatic disorders 135, nephrotic syndrome 79). Back pain was assessed by patient report, LS BMD was measured by dual‐energy X‐ray absorptiometry, and PVF were quantified on spine radiographs using the modified Genant semiquantitative method. Forty‐four patients (11.0%) had PVF. Logistic regression analysis between LS BMD and PVF produced an odds ratio (OR) of 1.9 (95% confidence interval CI, 1.5 to 2.5) per reduction in Z‐score unit, an area under the receiver operating characteristic curve of 0.70 (95% CI, 0.60 to 0.79), and an optimal BMD Z‐score cutoff of −1.6. Case identification using either low BMD alone (Z‐score < −1.6) or back pain alone gave similar results for sensitivity (55%, 52%, respectively), specificity (78%, 81%, respectively), positive predictive value (PPV; 24%, 25%, respectively), and negative predictive value (NPV; 93%, 93%, respectively). The paradigm using low BMD plus back pain produced lower sensitivity (32%), higher specificity (96%), higher PPV (47%), and similar NPV (92%). The approach using low BMD or back pain had the highest sensitivity (75%), lowest specificity (64%), lowest PPV (20%), and highest NPV (95%). All paradigms had increased sensitivities for higher fracture grades. Our results show that BMD and back pain history can be used to identify children with the highest risk of PVF so that radiography can be used judiciously. The specific paradigm to be applied will depend on the expected PVF rate and the clinical approach to the use of radiography. © 2019 American Society for Bone and Mineral Research.
Now That You Can Get What You Want, Can You Keep What You Need?
17-12-2019 – Dennis M. Black, Deborah E. Sellmeyer
Acetylcholinesterase Inhibitors Are Associated with Reduced Fracture Risk among Older Veterans with Dementia
12-12-2019 – Abayomi N Ogunwale, Cathleen S Colon‐Emeric, Richard Sloane, Robert A Adler, Kenneth W Lyles, Richard H Lee
ABSTRACTAcetylcholinesterase inhibitors (ACh
EIs) have been noted to increase bone density and quality in mice. Human studies are limited but suggest an association with improved bone healing after hip fracture. We examined the relationship between ACh
EI use and fracture risk in a national cohort of 360,015 male veterans aged 65 to 99 years with dementia but without prior fracture using Veterans Affairs (VA) hospital, Medicare, and pharmacy records from 2000 to 2010. Diagnosis of dementia, any clinical fracture (excluding facial and digital), comorbidities, and medications were identified using ICD‐9 and drug class codes. Cox proportional hazard models considering ACh
EI use as a time‐varying covariate and adjusting for fall and fracture risk factors compared the time‐to‐fracture in ACh
EI users versus non‐ACh
EI users. Potential confounders included demographics (age, race, body mass index), comorbidities associated with fracture or falls (diabetes, lung disease, stroke, Parkinsons, seizures, etc.) and medications associated with fracture or falls (bisphosphonates, glucocorticoids, androgen deprivation therapy ADT, proton pump inhibitors PPIs, selective serotonin receptor inhibitors SSRIs, etc.). Competing mortality risk was considered using the methods of Fine and Gray. To account for persistent effects on bone density or quality that might confer protection after stopping the medication, we completed a secondary analysis using the medication possession ratio (MPR) as a continuous variable in logistic regression models and also compared MPR increments of 10% to minimal/no use (MPR 0 to <0.10). Among older veterans with diagnosis of dementia, 20.1% suffered a fracture over an average of 4.6 years of follow‐up. Overall, 42.3% of the cohort were prescribed ACh
EIs during the study period. The hazard of any fracture among ACh
EI users compared with those on other/no dementia medications was significantly lower in fully adjusted models (hazard ratio HR = 0.81; 95% confidence interval CI 0.75–0.88). After considering competing mortality risk, fracture risk remained 18% lower in veterans using ACh
EIs (HR = 0.82; 95% CI 0.76–0.89). © 2019 American Society for Bone and Mineral Research. Published 2019. This article is a U.
S. Government work and is in the public domain in the USA.
Lactate Efflux From Intervertebral Disc Cells Is Required for Maintenance of Spine Health
12-12-2019 – Elizabeth S Silagi, Emanuel J Novais, Sara Bisetto, Aristeidis G Telonis, Joseph Snuggs, Christine L Le Maitre, Yunping Qiu, Irwin J Kurland, Irving M Shapiro, Nancy J Philp, Makarand V Risbud
ABSTRACTMaintenance of glycolytic metabolism is postulated to be required for health of the spinal column. In the hypoxic tissues of the intervertebral disc and glycolytic cells of vertebral bone, glucose is metabolized into pyruvate for ATP generation and reduced to lactate to sustain redox balance. The rise in intracellular H+/lactate concentrations are balanced by plasma‐membrane monocarboxylate transporters (MCTs). Using MCT4 null mice and human tissue samples, complemented with genetic and metabolic approaches, we determine that H+/lactate efflux is critical for maintenance of disc and vertebral bone health. Mechanistically, MCT4 maintains glycolytic and tricarboxylic acid (TCA) cycle flux and intracellular p
H homeostasis in the nucleus pulposus compartment of the disc, where hypoxia‐inducible factor 1α (HIF‐1α) directly activates an intronic enhancer in SLC16A3. Ultimately, our results provide support for research into lactate as a diagnostic biomarker for chronic, painful, disc degeneration. © 2019 American Society for Bone and Mineral Research.
Clinical and Biochemical Phenotypes in a Family with ENPP1 Mutations
11-12-2019 – Anupam Kotwal, Alejandro Ferrer, Rajiv Kumar, Ravinder J Singh, Vishakantha Murthy, Laura Schultz‐Rogers, Michael Zimmermann, Brandan Lanpher, Kristin Zimmerman, Paul R. Stabach, Eric Klee, Demetrios T. Braddock, Robert A. Wermers
ABSTRACTInactivating mutations of the ENPP1 gene are associated with generalized arterial calcification of infancy (GACI) and less often autosomal‐recessive hypophosphatemic rickets type 2 (ARHR2). We aimed to investigate the spectrum of phenotypes in a family with monoallelic and biallelic mutations of ENPP1 after identification through whole exome sequencing of a 54 year old female with biallelic mutation of ENPP1, c.323G > T; p.
Cys108Phe and c.1441C > T; p.
Arg481Trp. Including the proband, 2 subjects had biallelic mutations, 5 had monoallelic mutations, and 2 had no mutation of ENPP1. The maternal mutation, a known pathogenic variant associated with GACI, was found in 3 subjects with monoallelic mutations, while the paternal mutation which was not previously reported was present in 2 subjects with monoallelic mutations. Both subjects with biallelic mutations had bowing of bilateral femurs, periarticular mineral deposition, normocalcemic primary hyperparathyroidism with multi‐gland parathyroidectomy, increased carotid intima‐media thickness, and enthesopathy was also noted in one subject. Intact FGF23 was elevated in both subjects with biallelic mutations, while C‐terminal FGF23 was only elevated in one and PPi was reduced in one. Subjects with monoallelic mutations did not have periarticular calcifications or bone deformities. To conclude, patients with biallelic GACI causing mutations can survive well into adulthood, and despite the same biallelic ENPP1 pathogenic variants, clinical and biochemical manifestations can significantly differ, and include enthesopathy and primary hyperparathyroidism which have not been previously described. Although carriers of monoallelic ENPP1 variants appear unaffected by classic disease manifestations, there may be subtle biochemical and clinical findings that warrant further investigation.
This article is protected by copyright. All rights reserved.
Deterioration of Cortical and Trabecular Microstructure Identifies Women With Osteopenia or Normal Bone Mineral Density at Imminent and Long‐Term Risk for Fragility Fracture: A Prospective Study
10-12-2019 – Roland Chapurlat, Minh Bui, Elisabeth Sornay‐Rendu, Roger Zebaze, Pierre D. Delmas, Danny Liew, Eric Lespessailles, Ego Seeman
ABSTRACTMore than 70% of women sustaining fractures have osteopenia or “normal” bone mineral density (BMD). These women remain undetected using the BMD threshold of −2.5 SD for osteoporosis. As microstructural deterioration increases bone fragility disproportionate to the bone loss producing osteopenia/normal BMD, we hypothesized that the structural fragility score (SFS) of ≥70 units, a measure capturing severe cortical and trabecular deterioration, will identify these women. Distal radial images were acquired using high‐resolution peripheral quantitative tomography in postmenopausal French women, mean age 67 years (range 42–96 years); 1539 women were followed for 4 years (QUALYOR) and 561 women followed for 8 years (OFELY). Women with osteopenia or normal BMD accounted for ~80% of fractures. Women ≥70 years, 29.2% of the cohort, accounted for 39.2% to 61.5% of fractures depending on follow‐up duration. Women having fractures had a higher SFS, lower BMD, and a higher fracture risk assessment score (FRAX) than women remaining fracture‐free. In each BMD category (osteoporosis, osteopenia, normal BMD), fracture incidence was two to three times higher in women with SFS ≥70 than <70. In multivariable analyses, associations with fractures remained for BMD and SFS, not FRAX. BMD was no longer, or weakly, associated with fractures after accounting for SFS, whereas SFS remained associated with fracture after accounting for BMD. SFS detected two‐to threefold more women having fractures than BMD or FRAX. SFS in women with osteopenia/normal BMD conferred an odds ratio for fracture of 2.69 to 5.19 for women of any age and 4.98 to 12.2 for women ≥70 years. Receiver‐operator curve (ROC) analyses showed a significant area under the curve (AUC) for SFS, but not BMD or FRAX for the women ≥70 years of age. Targeting women aged ≥70 years with osteopenia indicated that treating 25% using SFS to allocate treatment conferred a cost‐effectiveness ratio < USD $21,000/QALY saved. Quantifying microstructural deterioration complements BMD by identifying women without osteoporosis at imminent and longer‐term fracture risk. © 2019 American Society for Bone and Mineral Research.
Sclerostin Antibody Treatment Increases Bone Mass and Normalizes Circulating Phosphate Levels in Growing Hyp Mice
10-12-2019 – Kelsey A Carpenter, Ryan D Ross
ABSTRACTX‐linked hypophosphatemia (XLH), caused by a loss‐of‐function mutation in the phosphate regulating gene with homology to endopeptidase located on the X chromosome (PHEX), is the most common form of vitamin D‐resistant rickets. Loss of functional PHEX results in elevated fibroblast growth factor 23 (FGF23) levels, impaired phosphate reabsorption, and inhibited skeletal mineralization. Sclerostin, a protein produced primarily in osteocytes, suppresses bone formation by antagonizing Wnt signaling and is reported to be elevated in XLH patients. This study used the Hyp mouse model to investigate sclerostins role in the pathophysiology of XLH by evaluating the use of a monoclonal antibody to sclerostin in a mouse model of XLH, the Hyp mouse. Male and female wild‐type and Hyp littermates were injected with 25 mg/kg of vehicle or sclerostin antibody (Scl‐Ab) twice weekly, beginning at 4 weeks of age and euthanized at 8 weeks of age. Scl‐Ab treatment increased serum phosphate levels and suppressed circulating levels of intact FGF23 in treated wild‐type and Hyp mice of both sexes. Cortical area, trabecular bone volume fraction (BV/TV), metaphyseal apparent density, and the peak load increased with Scl‐Ab treatment in both sexes. This short‐term treatment study suggests that Scl‐Ab treatment can effectively improve some of the pathologies associated with XLH, including normalization of phosphate, and that sclerostin may play a role in regulating FGF23 and phosphate metabolism in XLH. © 2019 American Society for Bone and Mineral Research.
Temporal Trends and Factors Associated with Bisphosphonate Discontinuation and Restart
10-12-2019 – Giovanni Adami, Ayesha Jaleel, Jeffrey R Curtis, Elizabeth Delzell, Rui Chen, Huifeng Yun, Shanette Daigle, Tarun Arora, Maria I Danila, Nicole C Wright, Suzanne M Cadarette, Amy Mudano, Jeffrey Foster, Kenneth G Saag
ABSTRACTAdverse events related to long‐term use of bisphosphonates have raised interest in temporary drug discontinuation. Trends in bisphosphonate discontinuation and restart, as well factors associated with these decisions, are not fully understood at a population level. We investigated temporal trends of bisphosphonate discontinuation from 2010 to 2015 and identified factors associated with discontinuation and restart of osteoporosis therapy. Our cohort consisted of long‐term bisphosphonate users identified from 2010 to 2015 Medicare data. We defined discontinuation as ≥12 months without bisphosphonate prescription claims. We used conditional logistic regression to compare factors associated with alendronate discontinuation or osteoporosis therapy restart in the 120‐day period preceding discontinuation or restart referent to the 120‐day preceding control periods. Among 73,800 long‐term bisphosphonate users, 59,251 (80.3%) used alendronate, 6806 (9.2%) risedronate, and 7743 (10.5%) zoledronic acid, exclusively. Overall, 26,281 (35.6%) discontinued bisphosphonates for at least 12 months. Discontinuation of bisphosphonates increased from 1.7% in 2010, reaching a peak of 14% in 2012 with levels plateauing through 2015. The factors most strongly associated with discontinuation of alendronate were: benzodiazepine prescription (adjusted odds ratio a
OR = 2.5; 95% confidence interval CI 2.1, 3.0), having a dual‐energy X‐ray absorptiometry (DXA) scan (a
OR = 1.8; 95% CI 1.7, 2.0), and skilled nursing facility care utilization (a
OR = 1.8; 95% CI 1.6, 2.1). The factors most strongly associated with restart of osteoporosis therapy were: having a DXA scan (a
OR = 9.9; 95% CI 7.7, 12.6), sustaining a fragility fracture (a
OR = 2.8; 95% CI 1.8, 4.5), and an osteoporosis or osteopenia diagnosis (a
OR = 2.5; 95% CI 2.0, 3.1). Our national evaluation of bisphosphonate discontinuation showed that an increasing proportion of patients on long‐term bisphosphonate therapy discontinue medications. The factors associated with discontinuation of alendronate were primarily related to worsening of overall health status, whereas traditional factors associated with worsening bone health were associated with restarting osteoporosis medication. © 2019 American Society for Bone and Mineral Research.
Clinical in Vivo Assessment of Bone Microarchitecture With CT Scanners: An Enduring Challenge
10-12-2019 – Doris My‐Lan Tran, Nicolas Vilayphiou, Bruno Koller
Human Heterozygous ENPP1 Deficiency Is Associated With Early Onset Osteoporosis, a Phenotype Recapitulated in a Mouse Model of Enpp1 Deficiency
05-12-2019 – Ralf Oheim, Kristin Zimmerman, Nathan D Maulding, Julian Stürznickel, Simon von Kroge, Dillon Kavanagh, Paul R Stabach, Uwe Kornak, Steven M Tommasini, Mark C Horowitz, Michael Amling, David Thompson, Thorsten Schinke, Björn Busse, Thomas O. Carpenter, Demetrios T Braddock
ABSTRACTBiallelic ENPP1 deficiency in humans induces generalized arterial calcification of infancy (GACI) and/or autosomal recessive hypophosphatemic rickets type 2 (ARHR2). The latter is characterized by markedly increased circulating FGF23 levels and renal phosphate wasting, but aberrant skeletal manifestations associated with heterozygous ENPP1 deficiency are unknown. Here, we report three adult men with early onset osteoporosis who presented with fractures in the thoracic spine and/or left radius, mildly elevated circulating FGF23, and hypophosphatemia. Total hip bone mineral density scans demonstrated osteoporosis (Z‐score < −2.5) and HRp
QCT demonstrated microarchitectural defects in trabecular and cortical bone. Next‐generation sequencing revealed heterozygous loss‐of‐function mutations in ENPP1 previously observed as biallelic mutations in infants with GACI. In addition, we present bone mass and structure data as well as plasma pyrophosphate (PPi) data of two siblings suffering from ARHR2 in comparison to their heterozygous and wild‐type family members indicative of an ENPP1 gene dose effect. The skeletal phenotype in murine Enpp1 deficiency yielded nearly identical findings. Ten‐week‐old male Enpp1 asj/asj mice exhibited mild elevations in plasma FGF23 and hypophosphatemia, and micro‐CT analysis revealed microarchitectural defects in trabecular and cortical bone of similar magnitude to HRp
QCT defects observed in humans. Histomorphometry revealed mild osteomalacia and osteopenia at both 10 and 23 weeks. The biomechanical relevance of these findings was demonstrated by increased bone fragility and ductility in Enpp1 asj/asj mice. In summary, ENPP1 exerts a gene dose effect such that humans with heterozygous ENPP1 deficiency exhibit intermediate levels of plasma analytes associated with bone mineralization disturbance resulting in early onset osteoporosis. © 2019 The Authors. Journal of Bone and Mineral Research published by American Society for Bone and Mineral Research.
Reply Letter to the Editor: Clinical in Vivo Assessment of Bone Microarchitecture With CT Scanners: An Enduring Challenge
05-12-2019 – Karen Mys, Peter Varga, Boyko Gueorguiev, Haniyeh Hemmatian, Filip Stockmans, G Harry Lenthe
Smoking and Alcohol Intake but Not Muscle Strength in Young Men Increase Fracture Risk at Middle Age: A Cohort Study Linked to the Swedish National Patient Registry
04-12-2019 – Daniel Prieto‐Alhambra, Aleksandra Turkiewicz, Carlen Reyes, Simon Timpka, Björn Rosengren, Martin Englund
ABSTRACTWe aimed to determine the relationship between handgrip strength, smoking, and alcohol consumption in young men and fracture risk at middle age. Thus, we carried out a cohort study including young men undergoing conscription examination in Sweden from September 1969 to May 1970 at a typical age of 18 years. Data on muscle strength, height, weight, and lifestyle factors were linked to the National Patient Register 1987–2010. Handgrip strength was considered the main exposure and smoking and alcohol consumption as secondary exposures. Outcomes were all fractures (except face, skull, digits), major osteoporotic fractures (thoracic/lumbar spine, proximal humerus, distal forearm or hip), and major traumatic fractures (shaft of humerus, forearm, femur, or lower leg) based on ICD‐9 and ‐10 codes. We used Cox regression models to estimate hazard ratios (HR) and 95% confidence intervals (CI) according to handgrip strength as a continuous variable (per 1 SD), after adjustment for weight, height, parental education, smoking, and alcohol consumption. A total of 40,112 men were included, contributing 892,572 person‐years. Overall, 3974 men fractured in middle age with the incidence rate (95% CI) of 44.5 (43.2–45.9) per 1000 person‐years. The corresponding rates were12.2 and 5.6 per 1000 person‐years for major osteoporotic and traumatic fractures, respectively. Handgrip strength‐adjusted HR (95% CI) was 1.01 (0.98–1.05), 0.94 (0.88–1.00), and 0.98 (0.88–1.08) per SD for all, major osteoporotic, and major traumatic fractures, respectively. Adjusted HR (95% CI) for smokers (>21 cigarettes/d) was 1.44 (1.21, 1.71) for all fractures, while the association between alcohol consumption and hazards of fracture was J‐shaped. Therefore, young adult handgrip strength was not associated with fracture risk in middle‐age men, although smoking and high alcohol consumption did confer an increased risk. © 2019 American Society for Bone and Mineral Research. © 2019 American Society for Bone and Mineral Research.
“An Inverse Agonist Ligand of the PTH Receptor Partially Rescues Skeletal Defects in a Mouse Model of Jansens Metaphyseal Chondrodysplasia”
04-12-2019 – Hiroshi Noda, Jun Guo, Ashok Khatri, Thomas Dean, Monica Reyes, Michael Armanini, Daniel J Brooks, Janaina S Martins, Ernestina Schipani, Mary L Bouxsein, Marie B Demay, John T Potts, Harald Jüppner, Thomas J Gardella
ABSTRACTJansens metaphyseal chondrodysplasia (JMC) is a rare disease of bone and mineral ion physiology that is caused by activating mutations in PTHR1. Ligand‐independent signaling by the mutant receptors in cells of bone and kidney results in abnormal skeletal growth, excessive bone turnover, and chronic hypercalcemia and hyperphosphaturia. Clinical features further include short stature, limb deformities, nephrocalcinosis, and progressive losses in kidney function. There is no effective treatment option available for JMC. In previous cell‐based assays, we found that certain N‐terminally truncated PTH and PTHr
P antagonist peptides function as inverse agonists and thus can reduce the high rates of basal cAMP signaling exhibited by the mutant PTHR1s of JMC in vitro. Here we explored whether one such inverse agonist ligand, Leu11,d
P(7‐36)NH2 (IA), can be effective in vivo and thus ameliorate the skeletal abnormalities that occur in transgenic mice expressing the PTHR1‐H223R allele of JMC in osteoblastic cells via the collagen‐1α1 promoter (C1HR mice). We observed that after 2 weeks of twice‐daily injection and relative to vehicle controls, the IA analog resulted in significant improvements in key skeletal parameters that characterize the C1HR mice, because it reduced the excess trabecular bone mass, bone marrow fibrosis, and levels of bone turnover markers in blood and urine. The overall findings provide proof‐of‐concept support for the notion that inverse agonist ligands targeted to the mutant PTHR1 variants of JMC can have efficacy in vivo. Further studies of such PTHR1 ligand analogs could help open paths toward the first treatment option for this debilitating skeletal disorder. © 2019 American Society for Bone and Mineral Research.
Back Pain‐Inducing Test, a Novel and Sensitive Screening Test for Painful Osteoporotic Vertebral Fractures: A Prospective Clinical Study
04-12-2019 – Huaijian Jin, Xiaoyuan Ma, Yaoyao Liu, Xiang Yin, Jun Zhu, Zhong Wang, Weili Fan, Yufei Jin, Jungang Pu, Jianhua Zhao, Mingyong Liu, Peng Liu
ABSTRACTTo detect painful vertebral fractures (VFs) in back pain populations at risk of osteoporosis, we designed a physical examination test (the Back Pain‐Inducing Test BPIT) that included three movements: lying supine, rolling over, and sitting up. If back pain is induced during any of these movements, the result is defined as positive, thereby establishing a presumptive diagnosis of painful VFs. Pain severity is quantified using a self‐reported numerical rating scale (NRS). The presence or absence of painful VFs is verified by whole‐spine magnetic resonance imaging (MRI), the gold standard for final diagnosis. According to the standards for reporting diagnostic accuracy, a real‐world, prospective, and observational study was performed on 510 back pain patients (enrolled from a single institute) at risk of osteoporosis. The sensitivity, specificity, and accuracy of the BPIT for identifying painful VFs were 99.1% (95% CI, 97.5% to 99.8%), 67.9% (95% CI, 60.4% to 74.5%), and 89.0%, respectively. The positive and negative predictive values were 86.6% (95% CI, 82.9% to 89.6%) and 97.4% (95% CI, 92.6% to 99.3%), respectively. Cutoff NRS scores for lying supine, rolling over, and sitting up were 3, 0, and 2, respectively. The corresponding area under the receiver operating characteristic curves (AUROCs) of each movement was 0.898 (95% CI, 0.868 to 0.922), 0.884 (95% CI, 0.854 to 0.911), and 0.910 (95% CI, 0.882 to 0.933), respectively. Although the high prevalence of VFs in the enrolled cohort partially limits the external validity of the predictive value in the general population, we conclude that the BPIT is potentially effective for detecting painful VFs in back pain populations at risk of osteoporosis. This test may be used as a stratification tool in decision‐making on subsequent imaging procedures: a negative BPIT rules out painful VFs and indicates that an MRI should be spared, whereas a positive BPIT means that an MRI is necessary and is likely to identify painful VFs. © 2019 American Society for Bone and Mineral Research.
Effect of Aerobic or Resistance Exercise, or Both, on Bone Mineral Density and Bone Metabolism in Obese Older Adults While Dieting: A Randomized Controlled Trial
04-12-2019 – Reina Armamento‐Villareal, Lina Aguirre, Debra L Waters, Nicola Napoli, Clifford Qualls, Dennis T Villareal
ABSTRACTWeight loss therapy of older adults with obesity is limited by weight loss–induced decrease in bone mineral density (BMD), which could exacerbate ongoing age‐related bone loss and increase the risk for fractures. Therefore, it is recommended that weight loss therapy of older adults with obesity should include an intervention such as regular exercise to reduce the concomitant bone loss. However, the most appropriate exercise types to combine with weight loss therapy in this older population is unknown. In a randomized controlled trial, we performed a head‐to‐head comparison of aerobic or resistance exercise, or both, during matched ~10% weight loss in 160 older adults with obesity. We measured changes in BMD (total hip, femoral neck, trochanter, intertrochanter, one‐third radius, lumbar spine) and bone markers. Changes between groups were analyzed using mixed‐model repeated measures analyses of variance. After 6 months of intensive lifestyle interventions, BMD decreased less in the resistance group (−0.006 g/cm2 −0.7%) and combination group (−0.012 g/cm2 −1.1%) than in the aerobic group (−0.027 g/cm2 −2.6%) (p = 0.001 for between‐group comparisons). Serum C‐telopeptide, procollagen type 1 N‐propeptide, and osteocalcin concentrations increased more in the aerobic group (33%, 16%, and 16%, respectively) than in the resistance group (7%, 2%, and 0%, respectively) and combination group (11%, 2%, and 5%, respectively) (p = 0.004 to 0.048 for between‐group comparisons). Multiple regression analyses revealed that the decline in whole body mass and serum leptin were the independent predictors of the decline in hip BMD (multiple R = 0.45 p < .001). These findings indicate that compared with aerobic exercise, resistance and combined aerobic and resistance exercise are associated with less weight loss–induced decrease in hip BMD and less weight loss–induced increase in bone turnover. Therefore, both resistance and combined aerobic and resistance exercise can be recommended to protect against bone loss during weight loss therapy of older adults with obesity. (LITOE Clinical
Trials.gov number NCT01065636.) © 2019 American Society for Bone and Mineral Research. Published 2019. This article is a U.
S. Government work and is in the public domain in the USA.
Prolonged Effect of Zoledronic Acid on Bone Mineral Density and Turnover in HIV‐Infected Adults on Tenofovir: A Randomized, Open‐Label Study
03-12-2019 – Andrew Carr, Stephen J Kerr, Robyn Richardson, Peter Ebeling, Nicholas Pocock, Jhon Rojas, Esteban Martinez, Jennifer Hoy, ZEST study Investigators
ABSTRACTZoledronic acid (ZOL) 5 mg annually was more effective than tenofovir disoproxil fumarate (TDF) switching at increasing bone mineral density (BMD) over 24 months in HIV‐infected, osteopenic adults. To determine whether the effects of ZOL would persist without further infusions, we compared changes in left hip and spine BMD over 36 months in participants randomized to ZOL 5 mg at baseline and month 12 (and to continue TDF) or to switch TDF (without receiving ZOL). We also compared changes in the plasma bone turnover markers (BTMs) C‐terminal telopeptide of type 1 collagen (CTX; bone resorption), and procollagen type 1 N propeptide (P1NP; bone formation) and determined whether CTX and P1NP changes at month 3 predicted BMD changes at month 36. Changes were compared in the per‐protocol populations, which included 32 (74%) of 43 participants randomized to ZOL and 37 (88%) of 42 participants who switched TDF. Despite not receiving ZOL after month 12, mean hip and spine BMD change from baseline were stable and remained greater with ZOL at month 36 than with TDF switching (spine: 7.5% versus 2.7%, mean difference 4.7%, p < 0.001; hip: 5.5% versus 1.5%, mean difference 4.0%, p < 0.001). CTX and P1NP levels declined in both groups but significantly more with ZOL. Only percent changes in P1NP at month 3 correlated inversely with BMD changes at month 36 (spine: rho = −0.442, p < 0.001; hip: rho = −0.373, p = 0.002). Two infusions of ZOL (in the presence of ongoing TDF) yielded sustained BMD increases through month 36 that remained greater than with TDF switching. © 2019 American Society for Bone and Mineral Research.
Vertebral Fracture Assessment Increases Use of Pharmacologic Therapy for Fracture Prevention in Clinical Practice
03-12-2019 – John T Schousboe, Lisa M Lix, Suzanne N Morin, Sheldon Derkatch, Mark Bryanton, Mashael Alhrbi, William D Leslie
ABSTRACTThe impact of vertebral fracture assessment (VFA) on lateral spine images in clinical practice on subsequent patient use of fracture prevention medication is unknown. Our objective was to determine the association of prevalent vertebral fracture identified on bone density lateral spine images (positive VFA) with subsequent use of fracture prevention therapy in usual clinical practice, using the Manitoba Bone Density Program database prospective observational cohort. Since 2010, targeted VFA imaging has been done at the time of bone densitometry in Manitoba for 21% of women and men meeting criteria based on age, bone mineral density (BMD), height loss, and glucocorticoid use. Among 6652 treatment‐naive individuals with at least 90 days follow‐up who had VFA imaging, 923 (13.9%) had one or more definite vertebral fractures identified using a modified algorithm‐based qualitative (ABQ) method. For those with a positive VFA, their bone density reports stated the patient was at high risk of subsequent fracture and qualified for fracture prevention therapy. Subsequent osteoporosis treatment initiated within the next 12 months was identified using population‐based pharmacy data. Logistic regression models were used to estimate the association of positive VFA with subsequent prescription (Rx), compared to negative VFA. Fracture prevention medication was started by 2127 (32%) individuals, 52.3% with positive versus 28.4% with negative VFA (p value <0.001). This association was substantially stronger in those designated (before VFA results were known) to have low or moderate fracture risk compared to high fracture risk (interaction p value <0.001), and in those with osteopenia (OR 4.51; 95% CI, 3.48 to 5.85) compared to those with osteoporosis by BMD criteria (OR 1.72; 95% CI, 1.43 to 2.08, interaction p value <0.001). Targeted VFA imaging at the time of bone densitometry substantially improves identification of those at high fracture risk and fracture prevention medication use among those with prevalent vertebral fracture. © 2019 American Society for Bone and Mineral Research. © 2019 American Society for Bone and Mineral Research.
Estradiol and Follicle‐Stimulating Hormone as Predictors of Onset of Menopause Transition‐Related Bone Loss in Pre‐ and Perimenopausal Women
03-12-2019 – Albert Shieh, Gail A Greendale, Jane A Cauley, Carrie Karvonen‐Gutierrez, Carolyn J Crandall, Arun S Karlamangla
ABSTRACTThe menopause transition (MT) may be an opportunity for early intervention to prevent rapid bone loss. To intervene early, we need to be able to prospectively identify pre‐ and perimenopausal women who are beginning to lose bone. This study examined whether estradiol (E2), or follicle‐stimulating hormone (FSH), measured in pre‐ and perimenopausal women, can predict significant bone loss by the next year. Bone loss was considered significant if bone mineral density (BMD) decline at the lumbar spine (LS) or femoral neck (FN) from a pre‐ or early perimenopausal baseline to 1 year after the E2 or FSH measurement was greater than the least detectable change. We used data from 1559 participants in the Study of Womens Health Across the Nation and tested E2 and FSH as separate predictors using repeated measures modified Poisson regression. Adjusted for MT stage, age, race/ethnicity, and body mass index, women with lower E2 (and higher FSH) were more likely to lose BMD: At the LS, each halving of E2 and each doubling of FSH were associated with 10% and 39% greater risk of significant bone loss, respectively (p < 0.0001 for each). At the FN, each halving of E2 and each doubling of FSH were associated with 12% (p = 0.01) and 27% (p < 0.001) greater risk of significant bone loss. FSH was more informative than E2 (assessed by the area under the receiver‐operator curve) at identifying women who were more versus less likely to begin losing bone, especially at the LS. Prediction was better when hormones were measured in pre‐ or early perimenopause than in late perimenopause. Tracking within‐individual change in either hormone did not predict onset of bone loss better than a single measure. We conclude that measuring FSH in the MT can help prospectively identify women with imminent or ongoing bone loss at the LS. © 2019 American Society for Bone and Mineral Research.
Hormone‐Independent Sexual Dimorphism in the Regulation of Bone Resorption by Krox20
03-12-2019 – Elias Sabag, Elinor Halperin, Tamar Liron, Sahar Hiram‐Bab, Baruch Frenkel, Yankel Gabet
ABSTRACTKrox20/EGR2 is a zinc finger transcription factor, implicated in the development of the hindbrain, nerve myelination, and tumor suppression. In skeletal biology, we have demonstrated that Krox20 also regulates adult bone metabolism. We and others have characterized several functions of Krox20 in the osteoclast lineage, namely, preosteoclast proliferation and differentiation, and mature osteoclast apoptosis. We have previously reported that systemically Krox20‐haploinsufficient mice have a low bone mass with increased bone resorption. However, new data have now revealed that this phenotype is restricted to females. In addition, we discovered that conditional knockout of Krox20 (c
KO) restricted to osteoclast progenitors is sufficient to induce the same female‐specific bone loss observed in systemic mutants. To test whether this sexual dimorphism results from an interaction between Krox20 and sex hormones, we examined the sex‐ and hormone‐dependent role of Krox20 deficiency on proliferation and apoptosis in osteoclastic cells. Our results indicate that male and female sex hormones (dihydrotestosterone DHT and estradiol E2, respectively) as well as Krox20 inhibit preosteoclast proliferation and augment osteoclast apoptosis. The observation that Krox20 expression is inhibited by DHT and E2 negates the hypothesis that the effect of sex hormones is mediated by an increase in Krox20 expression. Interestingly, the effect of Krox20 deficiency was observed only with cells derived from female animals, regardless of any sex hormones added in vitro. In addition, we have identified sexual dimorphism in the expression of several Krox20‐related genes, including NAB2. This sex‐specific epigenetic profile was established at puberty, maintained in the absence of sex hormones, and explains the female‐specific skeletal importance of Krox20. The findings described in this study emphasize the medical importance of sex differences, which may be determined at the epigenetic level. © 2019 American Society for Bone and Mineral Research.
Osteogenesis Imperfecta: Skeletal Outcomes After Bisphosphonate Discontinuation at Final Height
03-12-2019 – Marie‐Eve Robinson, Pamela Trejo, Telma Palomo, Francis H Glorieux, Frank Rauch
ABSTRACTIntravenous cyclical bisphosphonates are widely used to treat children with moderate to severe osteogenesis imperfecta (OI). Bisphosphonates are often discontinued when growth is completed, but subsequent skeletal changes have not been studied in detail. We assessed 31 patients (22 females) with OI who had started intravenous bisphosphonates (either pamidronate or zoledronic acid) before 13 years of age, were treated for at least 2 years (range 4.7–15.7 years), and discontinued treatment after completion of growth, when their age ranged from 13.4 to 20.0 years (mean 16.4 years). At 4 years after treatment discontinuation, lumbar spine areal bone mineral density (BMD) had increased by 4% (p < 0.05). Peripheral quantitative computed tomography of the radius showed a decrease in trabecular volumetric BMD at the distal metaphysis of 19% but an increase in cortical volumetric BMD of 4% (p < 0.05 for both). None of the patients sustained a new vertebral compression fracture during follow‐up. The proportion of patients with new long‐bone fractures was higher in the 2 years before treatment discontinuation than in the last 2 years of follow‐up (42% and 16%, respectively; p < 0.05). © 2019 American Society for Bone and Mineral Research.
Clinical Performance of the Updated Trabecular Bone Score (TBS) Algorithm, Which Accounts for the Soft Tissue Thickness: The OsteoLaus Study
03-12-2019 – Enisa Shevroja, Bérengère Aubry‐Rozier, Gabriel Hans, Elena Gonzalez Rodriguez, Delphine Stoll, Olivier Lamy, Didier Hans
ABSTRACTRegional soft tissue may have a noise effect on trabecular bone score (TBS) and eventually alter its estimate. The current TBS software (TBS i
Nsight®) is based on an algorithm accounting for body mass index (BMI) (TBSv3.03). We aimed to explore the updated TBS algorithm that accounts for soft tissue thickness (TBSv4.0). This study was embedded in the Osteo
Laus cohort of women in Lausanne, Switzerland. Hip and lumbar spine (LS) dual‐energy X‐ray absorptiometry (DXA) scans were performed using Discovery A System (Hologic). The incident major osteoporotic fractures (MOFs) were assessed from vertebral fracture assessments using Genants method (vertebral MOF) or questionnaires (nonvertebral MOF). We assessed the correlations of bone mineral density (BMD) or TBS with body composition parameters; MOF prediction ability of both versions of TBS; and the differences between Fracture Risk Assessment Tool (FRAX) adjusted for TBSv3.03 or TBSv4.0. In total, 1362 women with mean ± SD age 64.4 ± 7.5 years and mean ± SD BMI 25.9 ± 4.5 kg/m2 were followed for 4.4 years and 132 experienced an MOF. All the anthropometric measurements of our interest were positively correlated with LS, femoral neck, or hip BMD and TBSv4.0; whereas with TBSv3.03 their correlations were negative. In the models adjusted for age, soft tissue thickness, osteoporotic treatment, and LS‐BMD, for each SD decline in TBSv3.03, there was a 43% (OR 1.43; 95% CI, 1.12 to 1.83) increase in the odds of having MOF; whereas for each SD decline in TBSv4.0, there was a 54% (OR 1.54; 95% CI, 1.18 to 2.00) increase in the odds of having an MOF. Both FRAXs were very strongly correlated and the mild differences were present in the already high‐risk women for MOF. This study shows that TBSv4.0 overcomes the debatable residual negative correlation of the current TBS with body size and composition parameters, postulating itself as free from the previously acknowledged technical limitation of TBS. © 2019 American Society for Bone and Mineral Research.
Genetic Screening in a Large Chinese Cohort of Childhood Onset Hypoparathyroidism by Next‐Generation Sequencing Combined with TBX1‐MLPA
03-12-2019 – Yabing Wang, Min Nie, Ou Wang, Yuepeng Li, Yan Jiang, Mei Li, Weibo Xia, Xiaoping Xing
ABSTRACTAt least 15 candidate genes have been implicated in hypoparathyroidism (HP). However, comprehensive screening of causative genes for HP is lacking. Here, we investigated the genotype spectrum in a large group of Chinese patients with childhood onset HP. A total of 173 patients with childhood onset HP were analyzed using targeted next‐generation sequencing (NGS), including 15 candidate genes combined with multiplex ligation‐dependent probe amplification (MLPA) of the TBX1 gene. Twenty‐seven pathogenic or likely pathogenic mutations in five genes (TBX1, AIRE, GATA3, FAM111A, and CASR) including 13 novel variants in 23 patients, and 12 variants of uncertain clinical significance in five genes (GATA3, CASR, FAM111A, GCM2, and PTH) in 11 patients, were identified by NGS. Additionally, an entire gene deletion of TBX1 in 25 patients was found by TBX1‐MLPA. Combined with clinical data, 26 (15.0%) cases of Di
George syndrome (OMIM #188400), nine (5.2%) autoimmune polyglandular syndrome type 1 (OMIM #240300), eight (4.6%) autosomal dominant hypocalcemia type 1 (OMIM #601198), four (2.3%) hypoparathyroidism‐deafness‐renal dysplasia syndrome (OMIM #146255), and one (0.6%) Kenny‐Caffey syndrome type 2 (OMIM #127000) were verified. Among them, 16 of 26 (61.5%) Di
George syndrome cases were undiagnosed due to the lack of obvious clinical clues before genetic testing. The onset age of patients with mutations (median interquartile range, 2.8 0.1, 9.6 years) was significantly earlier than those without mutations (13.0 8.8, 15.0 years) (p < 0.001). Family history, early onset age, especially prior to 5 years old, and extraparathyroid manifestations were clues for hereditary HP. The combined targeted NGS and TBX‐1 MLPA were conveniently and effectively used for comprehensive genetic screening in this large Chinese cohort of childhood onset HP patients. Genetic defects were identified in 27.7% of early‐onset HP patients, including four kinds of syndromic HP and one isolated HP. A total of 13 novel mutations were detected, which expands the mutation spectrum of hypoparathyroidism. © 2019 American Society for Bone and Mineral Research.
Hop2 Interacts with ATF4 to Promote Osteoblast Differentiation
03-12-2019 – Yang Zhang, Tonghui Lin, Na Lian, Huan Tao, Cong Li, Lingzhen Li, Xiangli Yang
ABSTRACTActivating transcription factor 4 (ATF4) is a member of the basic leucine zipper (b
Zip) transcription factor family required for the terminal differentiation of osteoblasts. Despite its critical importance as one of the three main osteoblast differentiation transcription factors, regulators of osteoblast terminal maturation remain poorly defined. Here we report the identification of homologous pairing protein 2 (Hop2) as a dimerization partner of ATF4 in osteoblasts via the yeast two‐hybrid system. Deletional mapping revealed that the Zip domain of Hop2 is necessary and sufficient to bind ATF4 and to enhance ATF4‐dependent transcription. Ectopic Hop2 expression in preosteoblasts increased endogenous ATF4 protein content and accelerated osteoblast differentiation. Mice lacking Hop2 (Hop2−/−) have a normal stature but exhibit an osteopenic phenotype similar to the one observed in Atf4−/− mice, albeit milder, which is associated with decreased Osteocalcin m
RNA expression and reduced type I collagen synthesis. Compound heterozygous mice (Atf4+/−:Hop2+/−) display identical skeletal defects to those found in Hop2−/− mice. These results indicate that Hop2 plays a previous unknown role as a determinant of osteoblast maturation via its regulation of ATF4 transcriptional activity. Our work for the first time reveals a function of Hop2 beyond its role in guiding the alignment of homologous chromosomes. © 2019 American Society for Bone and Mineral Research.
Sclerostin Antibody–Induced Changes in Bone Mass Are Site Specific in Developing Crania
03-12-2019 – Amanda L Scheiber, David K Barton, Basma M Khoury, Joan C Marini, Donald L Swiderski, Michelle S Caird, Kenneth M Kozloff
ABSTRACTSclerostin antibody (Scl‐Ab) is an anabolic bone agent that has been shown to increase bone mass in clinical trials of adult diseases of low bone mass, such as osteoporosis and osteogenesis imperfecta (OI). Its use to decrease bone fragility in pediatric OI has shown efficacy in several growing mouse models, suggesting translational potential to pediatric disorders of low bone mass. However, the effects of pharmacologic inhibition of sclerostin during periods of rapid growth and development have not yet been described with respect to the cranium, where lifelong deficiency of functioning sclerostin leads to patterns of excessive bone growth, cranial compression, and facial palsy. In the present study, we undertook dimensional and volumetric measurements in the skulls of growing Brtl/+ OI mice treated with Scl‐Ab to examine whether therapy‐induced phenotypic changes were similar to those observed clinically in patients with sclerosteosis or Van Buchem disorder. Mice treated between 3 and 14 weeks of age with high doses of Scl‐Ab show significant calvarial thickening capable of rescuing OI‐induced deficiencies in skull thickness. Other changes in cranial morphology, such as lengths and distances between anatomic landmarks, intracranial volume, and suture interdigitation, showed minimal effects of Scl‐Ab when compared with growth‐induced differences over the treatment duration. Treatment‐induced narrowing of foramina was limited to sites of vascular but not neural passage, suggesting patterns of local regulation. Together, these findings reveal a site specificity of Scl‐Ab action in the calvaria with no measurable cranial nerve impingement or brainstem compression. This differentiation from the observed outcomes of lifelong sclerostin deficiency complements reports of Scl‐Ab treatment efficacy at other skeletal sites with the prospect of minimal cranial secondary complications. © 2019 American Society for Bone and Mineral Research. © 2019 American Society for Bone and Mineral Research.
TGFβ Inhibition Stimulates Collagen Maturation to Enhance Bone Repair and Fracture Resistance in a Murine Myeloma Model
03-12-2019 – Alanna C Green, Darren Lath, Katie Hudson, Brant Walkley, Jennifer M Down, Robert Owen, Holly R Evans, Julia Paton‐Hough, Gwendolen C Reilly, Michelle A Lawson, Andrew D Chantry
ABSTRACTMultiple myeloma is a plasma cell malignancy that causes debilitating bone disease and fractures, in which TGFβ plays a central role. Current treatments do not repair existing damage and fractures remain a common occurrence. We developed a novel low tumor phase murine model mimicking the plateau phase in patients as we hypothesized this would be an ideal time to treat with a bone anabolic. Using in vivo μCT we show substantial and rapid bone lesion repair (and prevention) driven by SD‐208 (TGFβ receptor I kinase inhibitor) and chemotherapy (bortezomib and lenalidomide) in mice with human U266‐GFP‐luc myeloma. We discovered that lesion repair occurred via an intramembranous fracture repair‐like mechanism and that SD‐208 enhanced collagen matrix maturation to significantly improve fracture resistance. Lesion healing was associated with VEGFA expression in woven bone, reduced osteocyte‐derived PTHr
P, increased osteoblasts, decreased osteoclasts, and lower serum tartrate‐resistant acid phosphatase 5b (TRACP‐5b). SD‐208 also completely prevented bone lesion development in mice with aggressive JJN3 tumors, and was more effective than an anti‐TGFβ neutralizing antibody (1D11). We also discovered that SD‐208 promoted osteoblastic differentiation (and overcame the TGFβ‐induced block in osteoblastogenesis) in myeloma patient bone marrow stromal cells in vitro, comparable to normal donors. The improved bone quality and fracture‐resistance with SD‐208 provides incentive for clinical translation to improve myeloma patient quality of life by reducing fracture risk and fatality. © 2019 American Society for Bone and Mineral Research.
RANKL Inhibition in Fibrous Dysplasia of Bone: A Preclinical Study in a Mouse Model of the Human Disease
03-12-2019 – Biagio Palmisano, Emanuela Spica, Cristina Remoli, Rossella Labella, Annamaria Di Filippo, Samantha Donsante, Fabiano Bini, Domenico Raimondo, Franco Marinozzi, Alan Boyde, Pamela Robey, Alessandro Corsi, Mara Riminucci
ABSTRACTFibrous dysplasia of bone/McCune‐Albright syndrome (Polyostotic FD/MAS; OMIM#174800) is a crippling skeletal disease caused by gain‐of‐function mutations of Gsα. Enhanced bone resorption is a recurrent histological feature of FD and a major cause of fragility of affected bones. Previous work suggests that increased bone resorption in FD is driven by RANKL and some studies have shown that the anti‐RANKL monoclonal antibody, denosumab, reduces bone turnover and bone pain in FD patients. However, the effect of RANKL inhibition on the histopathology of FD and its impact on the natural history of the disease remain to be assessed. In this study, we treated the EF1α‐GsαR201C mice, which develop an FD‐like phenotype, with an anti‐mouse RANKL monoclonal antibody. We found that the treatment induced marked radiographic and microscopic changes at affected skeletal sites in 2‐month‐old mice. The involved skeletal segments became sclerotic due to the deposition of new, highly mineralized bone within developing FD lesions and showed a higher mechanical resistance compared to affected segments from untreated transgenic mice. Similar changes were also detected in older mice with a full‐blown skeletal phenotype. The administration of anti‐mouse RANKL antibody arrested the growth of established lesions and, in young mice, prevented the appearance of new ones. However, after drug withdrawal, the newly formed bone was remodelled into FD tissue and the disease progression resumed in young mice. Taken together, our results show that the anti‐RANKL antibody significantly affected the bone pathology and natural history of FD in the mouse. Pending further work on the prevention and management of relapse after treatment discontinuation, our preclinical study suggests that RANKL inhibition may be an effective therapeutic option for FD patients. © 2019 American Society for Bone and Mineral Research.
Increased Risk of Bone Fractures in Hemodialysis Patients Treated with Proton Pump Inhibitors in Real World: Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS)
03-12-2019 – “Maria Fusaro, Graziella DArrigo, Annalisa Pitino, Giorgio Iervasi, Francesca Tentori, Bruce Robinson, Andrea Aghi, Brian Bieber, Keith Mccullogh, Fabrizio Fabris, Mario Plebani, Sandro Giannini, Maurizio Gallieni, Giovanni Tripepi”
ABSTRACTLong‐term treatment with proton pump inhibitors (PPIs) is associated with an increased risk of fractures in the general population. PPIs are widely prescribed to dialysis patients but to date no study has specifically tested, by state‐of‐art statistical methods, the relationship between use of PPIs and fractures in this patient population. This study aimed to assess whether use of PPIs is associated with bone fractures (ie, hip fractures and fractures other than hip fractures) in a large international cohort of hemodialysis patients. We considered an observational prospective cohort of 27,097 hemodialysis patients from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Data analysis was performed by the Fine and Gray method, considering the competitive risk of mortality, as well as by a cause‐specific hazards Cox model with death as a censoring event and matching patients according to the prescription time. Of 27,097 hemodialysis patients, 13,283 patients (49%) were on PPI treatment. Across the follow‐up period (median, 19 months), 3.8 bone fractures × 100 person‐years and 1.2 hip fractures × 100 person‐years occurred. In multiple Cox models, considering the competitive risk of mortality, the incidence rate of bone (subdistribution hazard ratio SHR 1.22; 95% CI, 1.10 to 1.36; p < 0.001) and hip fractures (SHR 1.35; 95% CI, 1.13 to 1.62; p = 0.001) was significantly higher in PPI‐treated than in PPI‐untreated patients. These findings also held true in multiple, cause‐specific, hazards Cox models matching patients according to the prescription time (bone fractures: HR 1.47; 95% CI, 1.23 to 1.76; p < 0.001; hip fractures: HR 1.85; 95% CI, 1.37 to 2.50; p < 0.001). The use of PPIs requires caution and a careful evaluation of risks/benefits ratio in hemodialysis patients. © 2019 American Society for Bone and Mineral Research.
Burosumab Improved Histomorphometric Measures of Osteomalacia in Adults with X‐Linked Hypophosphatemia: A Phase 3, Single‐Arm, International Trial
03-12-2019 – Karl L Insogna, Frank Rauch, Peter Kamenický, Nobuaki Ito, Takuo Kubota, Akie Nakamura, Lin Zhang, Matt Mealiffe, Javier San Martin, Anthony A Portale
ABSTRACTIn adults with X‐linked hypophosphatemia (XLH), excess FGF23 impairs renal phosphate reabsorption and suppresses production of 1,25‐dihydroxyvitamin D, resulting in chronic hypophosphatemia and persistent osteomalacia. Osteomalacia is associated with poor bone quality causing atraumatic fractures, pseudofractures, delayed fracture healing, and bone pain. Burosumab is a fully human monoclonal antibody against FGF23. UX023‐CL304 is an ongoing, open‐label, single‐arm, phase 3 study investigating the efficacy of subcutaneous burosumab, 1.0 mg/kg administered every 4 weeks, in improving osteomalacia in adults with XLH who have not been treated for at least 2 years before enrollment. The primary endpoint was improvement in osteoid volume/bone volume assessed by transiliac bone biopsies obtained at baseline and week 48. Additional assessments included serum phosphorus, markers of bone turnover, fracture/pseudofracture healing, and safety. Fourteen subjects enrolled, 13 completed 48 weeks, and 11 completed paired biopsies. All osteomalacia‐related histomorphometric measures improved significantly at week 48 (mean percent change: osteoid volume/bone volume, –54%, osteoid thickness, –32%, osteoid surface/bone surface, –26%, median mineralization lag time, –83%). Mean serum phosphorus concentration averaged across the mid‐point of the dose cycle between weeks 0 and 24 was 3.3 mg/d
L, a 50% increase from 2.2 mg/d
L at baseline. Markers of bone formation and resorption increased at week 48 (least squares LS mean increase: P1NP, +77%; CTx, +36%; both p < 0.0001). All subjects had one or more treatment‐emergent adverse event (AE). Most AEs were mild to moderate in severity. Two subjects experienced serious AEs (migraine; paresthesia) that were unrelated to treatment and resolved. Eleven subjects had 18 biopsy procedure‐related AEs: 14 for pain, two for itch, and one each for headache and bandage irritation. No deaths or incidents of hyperphosphatemia occurred. In conclusion, by normalizing phosphate homeostasis, burosumab significantly improved osteomalacia in adults with XLH, which likely explains the improved fracture healing and amelioration of skeletal complications. © 2019 The Authors. Journal of Bone and Mineral Research published by American Society for Bone and Mineral Research.
Fracture and Bone Mineral Density Response by Baseline Risk in Patients Treated With Abaloparatide Followed by Alendronate: Results From the Phase 3 ACTIVExtend Trial
03-12-2019 – Benjamin Z Leder, Carol Zapalowski, Ming‐Yi Hu, Gary Hattersley, Nancy E Lane, Andrea J Singer, Robin K Dore
ABSTRACTIn the randomized, placebo‐controlled, double‐blind phase 3 ACTIVE study (NCT01343004), 18 months of abaloparatide 80 μg daily (subcutaneous injection) in postmenopausal women at risk of osteoporotic fracture significantly reduced the risk of vertebral, nonvertebral, clinical, and major osteoporotic fractures and significantly increased bone mineral density (BMD) versus placebo regardless of baseline risk factors. Women from the abaloparatide and placebo groups who completed ACTIVE were eligible for ACTIVExtend (NCT01657162), in which all enrollees received sequential, open‐label monotherapy with alendronate 70 mg once weekly for up to 24 months. This prespecified analysis evaluated whether fracture risk reductions and bone mineral density (BMD) gains associated with abaloparatide during ACTIVE persisted through the full 43‐month ACTIVE–ACTIVExtend study period in nine prespecified baseline risk subgroups. Baseline risk subgroups included BMD T‐score at the lumbar spine, total hip, and femoral neck (≤ − 2.5 versus > − 2.5 and ≤ −3.0 versus > − 3.0), history of nonvertebral fracture (yes/no), prevalent vertebral fracture (yes/no), and age (<65 versus 65 to <75 versus ≥75 years). Forest plots display treatment effect. Treatment‐by‐subgroup interactions were tested using the Breslow‐Day test, Cox proportional hazards model, and ANCOVA model. After the combined ACTIVE–ACTIVExtend study period, reductions in relative risk for new vertebral, nonvertebral, clinical, and major osteoporotic fractures were greater among patients in the abaloparatide/alendronate group than among those in the placebo/alendronate group across all nine baseline risk subgroups. BMD gains at the lumbar spine, total hip, and femoral neck were greater in the abaloparatide/alendronate group versus the placebo/alendronate group. No clinically meaningful interaction between treatment assignment and any baseline risk variable was observed. The sequence of abaloparatide for 18 months followed by alendronate for up to 24 months appears to be an effective treatment option for a wide range of postmenopausal women at risk for osteoporotic fractures. © 2019 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals, Inc.
Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2‐Year Clinical Trial
03-12-2019 – Athanasios D Anastasilakis, Socrates E Papapoulos, Stergios A Polyzos, Natasha M Appelman‐Dijkstra, Polyzois Makras
ABSTRACTCessation of denosumab treatment is associated with increases in bone turnover above baseline values and rapid bone loss. We investigated the efficacy of zoledronate to prevent this bone loss in women with postmenopausal osteoporosis who were treated with denosumab (mean duration 2.2 years) and discontinued treatment after achieving osteopenia. Women were randomized to receive a single 5‐mg infusion of zoledronate (ZOL) (n = 27) or two additional 60‐mg injections of denosumab (Dmab) (n = 30). Both groups were followed for a total period of 24 months. At 24 months lumbar spine–bone mineral density (LS‐BMD) was not different from baseline in the ZOL group, but decreased in the Dmab group by (mean ± SD) 4.82% ± 0.7% (p < 0.001) from the 12‐month value; the difference in BMD changes between the two groups, the primary endpoint of the study, was statistically significant (p = 0.025). Results of femoral neck (FN)‐BMD changes were similar. ZOL infusion was followed by small but significant increases in serum procollagen type 1 N‐terminal propeptide (P1NP) and C‐terminal telopeptide of type 1 collagen (CTX) during the first year and stabilization thereafter. In the Dmab group, bone turnover marker values did not change during the first 12 months but increased significantly at 15 months and in the majority of women these remained elevated at 24 months. Neither baseline nor 12‐month bone turnover marker values were associated with BMD changes in either group of women. In the Dmab group, three patients sustained vertebral fractures (two patients multiple clinical, one patient morphometric) whereas one patient in the ZOL group sustained clinical vertebral fractures 12 months after the infusion. In conclusion, a single intravenous infusion of ZOL given 6 months after the last Dmab injection prevents bone loss for at least 2 years independently of the rate of bone turnover. Follow‐up is recommended, because in a few patients ZOL treatment might not have the expected effect at 2 years. © 2019 American Society for Bone and Mineral Research.
Cytokine‐Induced and Stretch‐Induced Sphingosine 1‐Phosphate Production by Enthesis Cells Could Favor Abnormal Ossification in Spondyloarthritis
03-12-2019 – Alaeddine El Jamal, Anne Briolay, Saida Mebarek, Benoit Le Goff, Frédéric Blanchard, David Magne, Leyre Brizuela, Carole Bougault
A) is a common rheumatic disease characterized by enthesis inflammation (enthesitis) and ectopic ossification (enthesophytes). The current pathogenesis model suggests that inflammation and mechanical stress are both strongly involved in Sp
A pathophysiology. We have previously observed that the levels of sphingosine 1‐phosphate (S1P), a bone anabolic molecule, were particularly high in Sp
A patients serum compared to healthy donors. Therefore, we wondered how this deregulation was related to Sp
A molecular mechanisms. Mouse primary osteoblasts, chondrocytes, and tenocytes were used as cell culture models. The sphingosine kinase 1 (Sphk1) gene expression and S1P secretion were significantly enhanced by cyclic stretch in osteoblasts and chondrocytes. Further, TNF‐α and IL‐17, cytokines implicated in enthesitis, increased Sphk1 m
RNA in chondrocytes in an additive manner when combined to stretch. The immunochemistry on mouse ankles showed that sphingosine kinase 1 (SK1) was localized in some chondrocytes; the addition of a pro‐inflammatory cocktail augmented Sphk1 expression in cultured ankles. Subsequently, fingolimod was used to block S1P metabolism in cell cultures. It inhibited S1P receptors (S1PRs) signaling and SK1 and SK2 activity in both osteoblasts and chondrocytes. Fingolimod also reduced S1PR‐induced activation by Sp
A patients synovial fluid (SF), demonstrating that the stimulation of chondrocytes by SFs from Sp
A patients involves S1P. In addition, when the osteogenic culture medium was supplemented with fingolimod, alkaline phosphatase activity, matrix mineralization, and bone formation markers were significantly reduced in osteoblasts and hypertrophic chondrocytes. Osteogenic differentiation was accompanied by an increase in S1prs m
RNA, especially S1P1/3, but their contribution to S1P‐impact on mineralization seemed limited. Our results suggest that S1P might be overproduced in Sp
A enthesis in response to cytokines and mechanical stress, most likely by chondrocytes. Moreover, S1P could locally favor the abnormal ossification of the enthesis; therefore, blocking the S1P metabolic pathway could be a potential therapeutic approach for the treatment of Sp
A. © 2019 American Society for Bone and Mineral Research.
“Clinical Guidelines on Pagets Disease of Bone”
03-12-2019 – “Stuart H Ralston, Luis Corral‐Gudino, Cyrus Cooper, Roger M Francis, William D Fraser, Luigi Gennari, Nuria Guanabens, M Kassim Javaid, Robert Layfield, Terence W ONeill, Robert Graham G Russell, Michael D Stone, Keith Simpson, Diana Wilkinson, Ruth Wills, M Carola Zillikens, Stephen P Tuck”
“Reply to Clinical Guidelines on Pagets Disease”
03-12-2019 – Bente Langdahl
First in Mice: RANKL Neutralization in Fibrous Dysplasia
03-12-2019 – Luis F Castro, PhD, Alison M Boyce, MD, Michael T Collins, MD
Ed Bd, Masthead, Comm List and TOC
Issue Information‐Declaration of Helsinki
JBMR Reviewer List 2019
IRS‐1 Functions as a Molecular Scaffold to Coordinate IGF‐I/IGFBP‐2 Signaling During Osteoblast Differentiation
03-12-2019 – Gang Xi, Xinchun Shen, Clifford J Rosen, David R Clemmons
Journal of Bone and Mineral Research: Volume 34, Number 12, December 2019
Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition
01-12-2019 – Robert B Conley, Gemma Adib, Robert A Adler, Kristina E Åkesson, Ivy M Alexander, Kelly C Amenta, Robert D Blank, William Timothy Brox, Emily E Carmody, Karen Chapman‐Novakofski, Bart L Clarke, Kathleen M Cody, Cyrus Cooper, Carolyn J Crandall, Douglas R Dirschl, Thomas J Eagen, Ann L Elderkin, Masaki Fujita, Susan L Greenspan, Philippe Halbout, Marc C Hochberg, Muhammad Javaid, Kyle J Jeray, Ann E Kearns, Toby King, Thomas F Koinis, Jennifer Scott Koontz, Martin Kužma, Carleen Lindsey, Mattias Lorentzon, George P Lyritis, Laura Boehnke Michaud, Armando Miciano, Suzanne N Morin, Nadia Mujahid, Nicola Napoli, Thomas P Olenginski, J Edward Puzas, Stavroula Rizou, Clifford J Rosen, Kenneth Saag, Elizabeth Thompson, Laura L Tosi, Howard Tracer, Sundeep Khosla, Douglas P Kiel
ABSTRACTOsteoporosis‐related fractures are undertreated, due in part to misinformation about recommended approaches to patient care and discrepancies among treatment guidelines. To help bridge this gap and improve patient outcomes, the American Society for Bone and Mineral Research assembled a multistakeholder coalition to develop clinical recommendations for the optimal prevention of secondary fracture among people aged 65 years and older with a hip or vertebral fracture. The coalition developed 13 recommendations (7 primary and 6 secondary) strongly supported by the empirical literature. The coalition recommends increased communication with patients regarding fracture risk, mortality and morbidity outcomes, and fracture risk reduction. Risk assessment (including fall history) should occur at regular intervals with referral to physical and/or occupational therapy as appropriate. Oral, intravenous, and subcutaneous pharmacotherapies are efficacious and can reduce risk of future fracture. Patients need education, however, about the benefits and risks of both treatment and not receiving treatment. Oral bisphosphonates alendronate and risedronate are first‐line options and are generally well tolerated; otherwise, intravenous zoledronic acid and subcutaneous denosumab can be considered. Anabolic agents are expensive but may be beneficial for selected patients at high risk. Optimal duration of pharmacotherapy is unknown but because the risk for second fractures is highest in the early post‐fracture period, prompt treatment is recommended. Adequate dietary or supplemental vitamin D and calcium intake should be assured. Individuals being treated for osteoporosis should be reevaluated for fracture risk routinely, including via patient education about osteoporosis and fractures and monitoring for adverse treatment effects. Patients should be strongly encouraged to avoid tobacco, consume alcohol in moderation at most, and engage in regular exercise and fall prevention strategies. Finally, referral to endocrinologists or other osteoporosis specialists may be warranted for individuals who experience repeated fracture or bone loss and those with complicating comorbidities (eg, hyperparathyroidism, chronic kidney disease). © 2019 American Society for Bone and Mineral Research.
Articular Cartilage Degradation and Aberrant Subchondral Bone Remodeling in Patients with Osteoarthritis and Osteoporosis
22-11-2019 – Linyang Chu, Xuqiang Liu, Zihao He, Xuequan Han, Mengning Yan, Xinhua Qu, Xiaofeng Li, Zhifeng Yu
ABSTRACTOsteoarthritis (OA) and osteoporosis (OP) are two skeletal disorders associated with joint structures. Occasionally, OA and OP occur in the same patient. However, the effect of OP changes on OA progression in patients with osteoporotic OA (OP‐OA) has not been reported, especially the potential association between subchondral bone and articular cartilage. Thus we investigated the alterations in the microstructure, biomechanical properties, and remodeling of subchondral bone as well as their association with cartilage damage in the hip joint of patients with OP‐OA. Thirty‐nine femoral head specimens were obtained from patients who underwent total hip arthroplasty (OA group, n = 19; OP‐OA group, n = 20), and healthy specimens from cadaver donors were used (control group, n = 10). The microstructure and biomechanical properties of subchondral bone were evaluated by micro–computed tomography and micro–finite‐element analysis. Histology, histomorphometric measurements, and immunohistochemistry were used to assess subchondral bone remodeling and cartilage damage. Linear regression analysis was performed to elucidate the relationship between subchondral bone and articular cartilage. In the subchondral bone of the OP‐OA group, compared with that of the OA group, aberrant bone remodeling leads to an inferior microstructure and worsening biomechanical properties, potentially affecting transmission of loading stress from the cartilage to the subchondral bone, and then resulting in accelerated OA progression in patients with OP‐OA. The results indicate that changes in subchondral bone could affect OA development and the improvement in subchondral bone with bone‐metabolism agents may help mitigate OA progression when OP and OA coexist in the same patients. © 2019 American Society for Bone and Mineral Research.
Circulating MicroRNA‐19b Identified From Osteoporotic Vertebral Compression Fracture Patients Increases Bone Formation
22-11-2019 – Mengge Sun, Liqiu Hu, Shang Wang, Tongling Huang, Minyi Zhang, Meng Yang, Wanxin Zhen, Dazhi Yang, William Lu, Min Guan, Songlin Peng
RNAs) play important roles in regulating gene expression and have been reported to be involved in various metabolic diseases, including osteoporosis. Although the transcriptional regulation of osteoblast differentiation has been well characterized, the role of circulating mi
RNAs in this process is poorly understood. Here we discovered that the level of circulating mi
R‐19b was significantly lower in osteoporotic patients with vertebral compression fractures than that of healthy controls. The expression level of mi
R‐19b was increased during osteoblastic differentiation of human mesenchymal stem cells (h
MSCs) and MC3T3‐E1 cells, and transfection with synthetic mi
R‐19b could promote osteoblastic differentiation of h
MSCs and MC3T3‐E1 cells. PTEN (phosphatase and tensin homolog deleted from chromosome 10) was found to be directly repressed by mi
R‐19b, with a concomitant increase in Runx2 expression and increased phosphorylation of AKT (protein kinase B, PKB). The expression level of circulating mi
R‐19b in aged ovariectomized mice was significantly lower than in young mice. Moreover, the osteoporotic bone phenotype in aged ovariectomized mice was alleviated by the injection of chemically modified mi
R‐19b). Taken together, our results show that circulating mi
R‐19b plays an important role in enhancing osteoblastogenesis, possibly through regulation of the PTEN/p
AKT/Runx2 pathway, and may be a useful therapeutic target in bone loss disorders, such as osteoporosis. © 2019 American Society for Bone and Mineral Research.
IFT80 Is Required for Fracture Healing Through Controlling the Regulation of TGF‐β Signaling in Chondrocyte Differentiation and Function
22-11-2019 – Min Liu, Mohammed Alharbi, Dana Graves, Shuying Yang
ABSTRACTPrimary cilia are essential cellular organelles that are anchored at the cell surface membrane to sense and transduce signaling. Intraflagellar transport (IFT) proteins are indispensable for cilia formation and function. Although major advances in understanding the roles of these proteins in bone development have been made, the mechanisms by which IFT proteins regulate bone repair have not been identified. We investigated the role of the IFT80 protein in chondrocytes during fracture healing by creating femoral fractures in mice with conditional deletion of IFT80 in chondrocytes utilizing tamoxifen inducible Col2α1‐Cre
ER mice. Col2α1cre
IFT80f/f mice had smaller fracture calluses than IFT80f/f (control) mice. The max‐width and max‐callus area were 31% and 48% smaller than those of the control mice, respectively. Col2α1cre
IFT80f/f mice formed low‐density/porous woven bony tissue with significantly lower ratio of bone volume, Trabecular (Tb) number and Tb thickness, and greater Tb spacing compared to control mice. IFT80 deletion significantly downregulated the expression of angiogenesis markers‐VEGF, PDGF and angiopoietin and inhibited fracture callus vascularization. Mechanistically, loss of IFT80 in chondrocytes resulted in a decrease in cilia formation and chondrocyte proliferation rate in fracture callus compared to the control mice. Meanwhile, IFT80 deletion downregulated the TGF‐β signaling pathway by inhibiting the expression of TGF‐βI, TGF‐βR, and phosphorylation of Smad2/3 in the fracture callus. In primary chondrocyte cultures in vitro, IFT80 deletion dramatically reduced chondrocyte proliferation, cilia assembly, and chondrogenic gene expression and differentiation. Collectively, our findings demonstrate that IFT80 and primary cilia play an essential role in fracture healing, likely through controlling chondrocyte proliferation and differentiation, and the TGF‐β signaling pathway. © 2019 American Society for Bone and Mineral Research.
Bone Marrow and Muscle Fat Infiltration Are Correlated among Postmenopausal Women With Osteoporosis: The AMBERS Cohort Study
20-11-2019 – Andy K Wong, Abinaa Chandrakumar, Rachel Whyte, Shannon Reitsma, Hana Gillick, Anthony Pokhoy, Alexandra Papaioannou, Jonathan D Adachi
ABSTRACTBone and muscle have shown to interact, but little is known about fat within bone and muscle. Clinical studies have isolated fat within bone and muscle using MRI. In this cross‐sectional study, we hypothesized that bone marrow adiposity and muscle adiposity are related and that this relationship is associated with osteoporosis. Postmenopausal women aged 60 to 85 years were recruited as part of the Appendicular Muscle and Bone Extension Research Study (AMBERS). Participants completed dual‐energy X‐ray absorptiometry (DXA) of the hip and spine to diagnose osteoporosis. Muscle adiposity was measured with MRI at the 66% site of the leg. Fat segmentation was achieved using a semi‐automated iterative threshold‐optimizing algorithm (error < 5%). Peripheral quantitative computed tomography measured marrow density of the 4% distal tibia (surrogate for marrow fat) by threshold‐based, edge‐detection segmentations and by examining residuals from trabecular bone density regressed on trabecular tissue mineral density. Muscle adiposity from MRI was regressed on marrow density using linear regression. Models were further examined with an interaction with osteoporosis status. Among 312 women (aged 75.4 ± 5.9 years, body mass index BMI 29.5 ± 5.7 kg/m2), a larger amount of muscle fat was associated with lower marrow density at the 66% mid‐tibia (B = 84.08 27.56, p = 0.002) and at the 4% distal tibia (B = 129.17 55.96, p = 0.022) after accounting for age, height, weight, average daily energy expenditure, hypertension, and diabetes. Interactions of this relationship with osteoporosis status were also significant. Upon probing these interactions, the relationships were significant only in women with osteoporosis but not in those without osteoporosis. Fat from bone marrow and muscle may be related to one another through the same phenomenon, which is likely also responsible for osteoporosis, but independent of hypertension and diabetes. More research should focus on the potential abnormalities in muscle and bone fat metabolism and mesenchymal cell commitment to fat within patients with osteoporosis. © 2019 American Society for Bone and Mineral Research.
High Plasma Erythropoietin Predicts Incident Fractures in Elderly Men with Normal Renal Function: The MrOS Sweden Cohort
20-11-2019 – Hallgerdur Lind Kristjansdottir, Catharina Lewerin, Ulf H. Lerner, Hans Herlitz, Peter Johansson, Helena Johansson, Magnus Karlsson, Mattias Lorentzon, Claes Ohlsson, Östen Ljunggren, Dan Mellström
ABSTRACTPreclinical studies on the role of erythropoietin (EPO) in bone metabolism are contradictory. Regeneration models indicate an anabolic effect on bone healing, whereas models on physiologic bone remodeling indicate a catabolic effect on bone mass. No human studies on EPO and fracture risk are available. It is known that fibroblast growth factor 23 (FGF23) affects bone mineralization and that serum concentration of FGF23 is higher in men with decreased estimated glomerular filtration rate (e
GFR). Recently, a direct association between EPO and FGF23 has been shown. We have explored the potential association between EPO and bone mineral density (BMD), fracture risk, and FGF23 in humans. Plasma levels of EPO were analyzed in 999 men (aged 69 to 81 years), participating in the Gothenburg part of the population‐based Osteoporotic Fractures in Men (Mr
OS) study, Mr
OS Sweden. The mean ± SD EPO was 11.5 ± 9.0 IU/L. Results were stratified by e
GFR 60 m
L/min. For men with e
GFR ≥60 m
L/min (n = 728), EPO was associated with age (r = 0.13, p < 0.001), total hip BMD (r = 0.14, p < 0.001), intact (i)FGF23 (r = 0.11, p = 0.004), and osteocalcin (r = −0.09, p = 0.022). The association between total hip BMD and EPO was independent of age, body mass index (BMI), i
FGF23, and hemoglobin (beta = 0.019, p < 0.001). During the 10‐year follow‐up, 164 men had an X‐ray–verified fracture, including 117 major osteoporotic fractures (MOF), 39 hip fractures, and 64 vertebral fractures. High EPO was associated with higher risk for incident fractures (hazard ratio HR = 1.43 per tertile EPO, 95% confidence interval CI 1.35–1.63), MOF (HR = 1.40 per tertile EPO, 95% CI 1.08–1.82), and vertebral fractures (HR = 1.42 per tertile EPO, 95% CI 1.00–2.01) in a fully adjusted Cox regression model. In men with e
L/min, no association was found between EPO and BMD or fracture risk. We here demonstrate that high levels of EPO are associated with increased fracture risk and increased BMD in elderly men with normal renal function. © 2019 American Society for Bone and Mineral Research.
Some Questions About the Article “The Efficacy and Safety of Vertebral Augmentation: A Second ASBMR Task Force Report”
19-11-2019 – Lei Ning, Shuanglin Wan, Shunwu Fan
Response to: Some Questions About the Article “The Efficacy and Safety of Vertebral Augmentation: A Second ASBMR Task Force Report”
19-11-2019 – Rachelle Buchbinder, Peter R Ebeling, Kristina Akesson, Douglas C Bauer, Richard Eastell, Howard A Fink, Lora Giangregorio, Nuria Guanabens, Deborah Kado, David Kallmes, Wendy Katzman, Alexander Rodriguez, Robert Wermers, H Alexander Wilson, Mary L Bouxsein
HR‐pQCT Measures of Bone Microarchitecture Predict Fracture: Systematic Review and Meta‐Analysis
19-11-2019 – Nicholas Mikolajewicz, Nick Bishop, Andrew J Burghardt, Lars Folkestad, Anthony Hall, Kenneth M Kozloff, Pauline T Lukey, Michael Molloy‐Bland, Suzanne N Morin, Amaka C Offiah, Jay Shapiro, Bert Rietbergen, Kim Wager, Bettina M Willie, Svetlana V Komarova, Francis H Glorieux
ABSTRACTHigh‐resolution peripheral quantitative computed tomography (HR‐p
QCT) is a noninvasive imaging modality for assessing volumetric bone mineral density (v
BMD) and microarchitecture of cancellous and cortical bone. The objective was to (1) assess fracture‐associated differences in HR‐p
QCT bone parameters; and (2) to determine if HR‐p
QCT is sufficiently precise to reliably detect these differences in individuals. We systematically identified 40 studies that used HR‐p
QCT (39/40 used Xtreme
CT scanners) to assess 1291 to 3253 and 3389 to 10,687 individuals with and without fractures, respectively, ranging in age from 10.9 to 84.7 years with no comorbid conditions. Parameters describing radial and tibial bone density, microarchitecture, and strength were extracted and percentage differences between fracture and control subjects were estimated using a random effects meta‐analysis. An additional meta‐analysis of short‐term in vivo reproducibility of bone parameters assessed by Xtreme
CT was conducted to determine whether fracture‐associated differences exceeded the least significant change (LSC) required to discern measured differences from precision error. Radial and tibial HR‐p
QCT parameters, including failure load, were significantly altered in fracture subjects, with differences ranging from −2.6% (95% confidence interval CI −3.4 to −1.9) in radial cortical v
BMD to −12.6% (95% CI −15.0 to −10.3) in radial trabecular v
BMD. Fracture‐associated differences reported by prospective studies were consistent with those from retrospective studies, indicating that HR‐p
QCT can predict incident fracture. Assessment of study quality, heterogeneity, and publication biases verified the validity of these findings. Finally, we demonstrated that fracture‐associated deficits in total and trabecular v
BMD and certain tibial cortical parameters can be reliably discerned from HR‐p
QCT‐related precision error and can be used to detect fracture‐associated differences in individual patients. Although differences in other HR‐p
QCT measures, including failure load, were significantly associated with fracture, improved reproducibility is needed to ensure reliable individual cross‐sectional screening and longitudinal monitoring. In conclusion, our study supports the use of HR‐p
QCT in clinical fracture prediction. © 2019 American Society for Bone and Mineral Research.
Targeting Bortezomib to Bone Increases Its Bone Anabolic Activity and Reduces Systemic Adverse Effects in Mice
19-11-2019 – Hua Wang, Hengwei Zhang, Venkat Srinivasan, Jianguo Tao, Wen Sun, Xi Lin, Tao Wu, Brendan F Boyce, Frank H Ebetino, Robert K Boeckman, Lianping Xing
ABSTRACTBortezomib (Btz) is a proteasome inhibitor approved by the FDA to treat multiple myeloma. It also increases bone volume by promoting osteoblast differentiation and inhibiting osteoclastogenesis in mice. However, Btz has severe systemic adverse effects, which would limit its use as a bone anabolic agent. Here, we designed and synthesized a bone‐targeted form of Btz by conjugating it to a bisphosphonate (BP) with no antiresorptive activity. We report that BP‐Btz inhibited osteoclast formation and bone resorption and stimulated osteoblast differentiation in vitro similar to Btz. In vivo, BP‐Btz increased bone volume more effectively than Btz in three mouse models: untreated wild‐type mice, mice with ovariectomy, and aged mice with tibial factures. Importantly, BP‐Btz had significantly less systemic side effects than Btz, including less thymic cell death, sympathetic nerve damage, and thrombocytopenia, and it improved survival rates in aged mice. Thus, BP‐Btz represents a novel anabolic agent to treat conditions, such as postmenopausal and age‐related bone loss. Bone targeting is an attractive approach to repurpose approved drugs to treat skeletal diseases. © 2019 American Society for Bone and Mineral Research. © 2019 American Society for Bone and Mineral Research.
Nonremission and Recurrent Tumor‐Induced Osteomalacia: A Retrospective Study
15-11-2019 – Xiang Li, Yan Jiang, Li Huo, Huanwen Wu, Yong Liu, Jin Jin, Wei Yu, Wei Lv, Lian Zhou, Yu Xia, Ou Wang, Mei Li, Xiaoping Xing, Yue Chi, Ruizhi Jiajue, Lijia Cui, Xunwu Meng, Weibo Xia
ABSTRACTTumor‐induced osteomalacia (TIO) is a rare paraneoplastic syndrome. It is curable by excision of the causative tumor. However, a few cases may persist or relapse after tumor resection. We aimed to investigate the rate of these events and related factors. We retrospectively studied TIO patients treated with surgery in a tertiary hospital. TIO was established based on a pathologic examination or the reversion of hypophosphatemia. Refractory TIO patients consisted of those with nonremission or recurrent hypophosphatemia after surgery. A total of 230 patients were confirmed as having TIO. After primary surgery, 26 (11.3%) cases persisted, and 16 (7.0%) cases recurred. The overall refractory rate was 18.3%. The median time of recurrence was 33 months. Compared with patients in the recovery group, patients in the refractory group were more likely to be female (59.5% versus 41.0%, p = .029) and have a lower serum phosphate level (0.44 ± 0.13 versus 0.50 ± 0.11 mmol/L, p = .002). The refractory rate was lowest in head/neck tumors (7.5%) and highest in spine tumors (77.8%). Regarding the tissue involved of tumor location, the refractory rate was higher in tumors involving bone than tumors involving soft tissue (32.7% versus 7.0%, p < .001). The outcomes of malignant tumors were worse than those of benign tumors (p < .001): nonremission rate, 21.4% versus 9.7%; recurrence rate, 28.6% versus 6.5%. In the multivariate regression analysis, female sex, spine tumors, bone tissue‐involved tumors, malignancy, and low preoperation serum phosphorus levels were identified as risk factors for refractory outcomes. High preoperative fibroblast growth factor 23 (FGF23) levels were also associated with refractory after adjusting for involving tissue and tumor malignancy. In summary, we are the first to report the rate and clinical characteristics of refractory TIO in a large cohort. For patients with multiple risk factors, especially spine tumors, clinical practitioners should be aware of a poor surgical prognosis. © 2019 The Authors. Journal of Bone and Mineral Research published by American Society for Bone and Mineral Research.
The Associations Between Seven Different Types of Physical Activity and the Incidence of Fracture at Seven Sites in Healthy Postmenopausal UK Women
15-11-2019 – Miranda EG Armstrong, Jason Lacombe, Clare J Wotton, Benjamin J Cairns, Jane Green, Sarah Floud, Valerie Beral, Gillian K Reeves, for the Million Women Study Collaborators
ABSTRACTThere is a paucity of information on associations between specific types of physical activity and fracture risk at different sites in otherwise healthy postmenopausal women. Therefore, we examined risk of fracture at seven different sites associated with seven different types of physical activity in the population‐based prospective UK Million Women Study. A total of 371,279 postmenopausal women (mean age 59.8 years), rating their health as good or excellent and reporting participation in walking, cycling, gardening, doing housework, yoga, dance, and sports club activities, were followed for site‐specific incident fracture through record linkage to national databases on day‐case and overnight hospital admissions. Cox regression yielded adjusted relative risks (RRs) and, because of the large number of statistical tests done, 99% confidence intervals (CIs) for fracture at seven different sites in relation to seven different physical activities. During an average follow‐up of 12 years, numbers with a first site‐specific fracture were as follows: humerus (2341), forearm (1238), wrist (7358), hip (4354), femur (not neck) (617), lower leg (1184), and ankle (3629). For upper limb fractures there was significant heterogeneity across the seven activity types (test for heterogeneity p = 0.004), with gardening more than 1 hour/week associated with a lower risk (RR = 0.91; 99% CI, 0.86 to 0.96; p < 0.0001), whereas cycling more than 1 hour/week was associated with an increased risk (RR = 1.11; 99% CI, 1.00 to 1.23; p = 0.008). For fractures of the lower limb (including hip) there was no significant heterogeneity by type of activity, with significant approximately 5% to 15% reductions in risk associated with most activities, except cycling. For hip fractures, there was no significant heterogeneity by type of activity, but with significant 15% to 20% reductions in risk associated with walking for 1 hour/day and participating in yoga and sporting activities. Physical activity is a modifiable risk factor for fracture, but the effects differ between different types of activities and different fracture sites. © 2019 The Authors. Journal of Bone and Mineral Research published by American Society for Bone and Mineral Research.
Kidney Disease Progression Does Not Decrease Intestinal Phosphorus Absorption in a Rat Model of Chronic Kidney Disease–Mineral Bone Disorder
15-11-2019 – Colby J Vorland, Annabel Biruete, Pamela J Lachcik, Shruthi Srinivasan, Neal X Chen, Sharon M Moe, Kathleen M Hill Gallant
ABSTRACTThe Cy/+ rat has been characterized as a progressive model of chronic kidney disease–mineral bone disorder (CKD‐MBD). We aimed to determine the effect of kidney disease progression on intestinal phosphorus absorption and whole‐body phosphorus balance in this model. A total of 48 Cy/+ (CKD) and 48 normal littermates (NL) rats were studied at two ages: 20 weeks and 30 weeks, to model progressive kidney function decline at approximately 50% and 20% of normal kidney function. Sodium‐dependent and sodium‐independent intestinal phosphorus absorption efficiency were measured by the in situ jejunal ligated loop method using 33P radioisotope. Our results show that CKD rats had slightly higher sodium‐dependent phosphorus absorption compared to NL rats, and absorption decreased from 20 to 30 weeks. These results are in contrast to plasma 1,25OH2D, which was lower in CKD rats. Gene expression of the major intestinal phosphorus transporter, Na
Pi‐2b, was not different between CKD and NL rats in the jejunum but was lower in CKD rats versus NL rats in the duodenum. Jejunal ligated loop phosphorus absorption results are consistent with percent net phosphorus absorption results obtained from metabolic balance: higher net percent phosphorus absorption values in CKD rats compared with NL, and lower values in 30‐week‐olds compared with 20‐week‐olds. Phosphorus balance was negative (below zero) in CKD rats, significantly lower in 30‐week‐old rats compared with 20‐week‐old rats, and lower in CKD rats compared with NL rats at both ages. These results demonstrate no reduction in intestinal phosphorus absorption with progression of CKD despite lower 1,25OH2D status when assessed by an in situ ligated loop test, which is in contrast to the majority of in vitro studies, and if confirmed in further studies, could challenge the physiological relevance of in vitro findings. © 2019 American Society for Bone and Mineral Research.
A Rare Mutation in SMAD9 Associated With High Bone Mass Identifies the SMAD‐Dependent BMP Signaling Pathway as a Potential Anabolic Target for Osteoporosis
14-11-2019 – Celia L Gregson, Dylan J. M. Bergen, Paul Leo, Richard B Sessions, Lawrie Wheeler, April Hartley, Scott Youlten, Peter I Croucher, Aideen M McInerney‐Leo, William Fraser, Jonathan CY Tang, Lisa Anderson, Mhairi Marshall, Leon Sergot, Lavinia Paternoster, George Davey Smith, The AOGC Consortium, Matthew A Brown, Chrissy Hammond, John P Kemp, Jon H Tobias, Emma L Duncan
ABSTRACTNovel anabolic drug targets are needed to treat osteoporosis. Having established a large national cohort with unexplained high bone mass (HBM), we aimed to identify a novel monogenic cause of HBM and provide insight into a regulatory pathway potentially amenable to therapeutic intervention. We investigated a pedigree with unexplained HBM in whom previous sequencing had excluded known causes of monogenic HBM. Whole exome sequencing identified a rare (minor allele frequency 0.0023), highly evolutionarily conserved missense mutation in SMAD9 (c.65T>C, p.
Leu22Pro) segregating with HBM in this autosomal dominant family. The same mutation was identified in another two unrelated individuals both with HBM. In silico protein modeling predicts the mutation severely disrupts the MH1 DNA‐binding domain of SMAD9. Affected individuals have bone mineral density (BMD) Z‐scores +3 to +5, mandible enlargement, a broad frame, torus palatinus/mandibularis, pes planus, increased shoe size, and a tendency to sink when swimming. Peripheral quantitative computed tomography (p
QCT) measurement demonstrates increased trabecular volumetric BMD and increased cortical thickness conferring greater predicted bone strength; bone turnover markers are low/normal. Notably, fractures and nerve compression are not found. Both genome‐wide and gene‐based association testing involving estimated BMD measured at the heel in 362,924 white British subjects from the UK Biobank Study showed strong associations with SMAD9 (PGWAS = 6 × 10−16; PGENE = 8 × 10−17). Furthermore, we found Smad9 to be highly expressed in both murine cortical bone–derived osteocytes and skeletal elements of zebrafish larvae. Our findings support SMAD9 as a novel HBM gene and a potential novel osteoanabolic target for osteoporosis therapeutics. SMAD9 is thought to inhibit bone morphogenetic protein (BMP)‐dependent target gene transcription to reduce osteoblast activity. Thus, we hypothesize SMAD9 c.65T>C is a loss‐of‐function mutation reducing BMP inhibition. Lowering SMAD9 as a potential novel anabolic mechanism for osteoporosis therapeutics warrants further investigation. © 2019 The Authors. Journal of Bone and Mineral Research published by American Society for Bone and Mineral Research.
Greater Bone Marrow Adiposity Predicts Bone Loss in Older Women
14-11-2019 – Gina N Woods, Susan K Ewing, Sigurdur Sigurdsson, Deborah M Kado, Gudny Eiriksdottir, Vilmundur Gudnason, Trisha F Hue, Thomas F Lang, Eric Vittinghoff, Tamara B Harris, Clifford Rosen, Kaipin Xu, Xiaojuan Li, Ann V Schwartz
ABSTRACTBone marrow adiposity (BMA) is associated with aging and osteoporosis, but whether BMA can predict bone loss and fractures remains unknown. Using data from the Age Gene/Environment Susceptibility (AGES)‐Reykjavik study, we investigated the associations between 1H‐MRS–based measures of vertebral bone marrow adipose tissue (BMAT), annualized change in bone density/strength by quantitative computed tomography (QCT) and DXA, and secondarily, with incident clinical fractures and radiographic vertebral fractures among older adults. The associations between BMAT and annualized change in bone density/strength were evaluated using linear regression models, adjusted for age, body mass index (BMI), diabetes, estradiol, and testosterone. Cox proportional hazards models were used to evaluate the associations between baseline BMAT and incident clinical fractures, and logistic regression models for incident vertebral fractures. At baseline, mean ± SD age was 80.9 ± 4.2 and 82.6 ± 4.2 years in women (n = 148) and men (n = 150), respectively. Mean baseline BMAT was 55.4% ± 8.1% in women and 54.1% ± 8.2% in men. Incident clinical fractures occurred in 7.4% of women over 2.8 years and in 6.0% of men over 2.2 years. Incident vertebral fractures occurred in 12% of women over 3.3 years and in 17% of men over 2.7 years. Each 1 SD increase in baseline BMAT was associated with a 3.9 mg2/cm4/year greater loss of spine compressive strength index (p value = .003), a 0.9 mg/cm3/year greater loss of spine trabecular BMD (p value = .02), and a 1.2 mg/cm3/year greater loss of femoral neck trabecular BMD (p value = .02) in women. Among men, there were no associations between BMAT and changes in bone density/strength. There were no associations between BMAT and incident fractures in women or men. In conclusion, we found greater BMAT is associated with greater loss of trabecular bone at the spine and femoral neck, and greater loss of spine compressive strength, in older women. © 2019 American Society for Bone and Mineral Research.
Effects of Estrogen Replacement on Bone Geometry and Microarchitecture in Adolescent and Young Adult Oligoamenorrheic Athletes: A Randomized Trial
07-11-2019 – Kathryn E Ackerman, Vibha Singhal, Meghan Slattery, Kamryn T Eddy, Mary L Bouxsein, Hang Lee, Anne Klibanski, Madhusmita Misra
ABSTRACTOligoamenorrheic athletes (OAs) have lower bone mineral density (BMD) and greater impairment of bone microarchitecture, and therefore higher fracture rates compared to eumenorrheic athletes. Although improvements in areal BMD (a
BMD; measured by dual‐energy X‐ray absorptiometry) in OAs have been demonstrated with transdermal estrogen treatment, effects of such treatment on bone microarchitecture are unknown. Here we explore effects of transdermal versus oral estrogen versus no estrogen on bone microarchitecture in OA. Seventy‐five OAs (ages 14 to 25 years) were randomized to (i) a 100‐μg 17β‐estradiol transdermal patch (PATCH) administered continuously with 200 mg cyclic oral micronized progesterone; (ii) a combined 30 μg ethinyl estradiol and 0.15 mg desogestrel pill (PILL); or (iii) no estrogen/progesterone (NONE) and were followed for 12 months. Calcium (≥1200 mg) and vitamin D (800 IU) supplements were provided to all. Bone microarchitecture was assessed using high‐resolution peripheral quantitative CT at the distal tibia and radius at baseline and 1 year. At baseline, randomization groups did not differ by age, body mass index, percent body fat, duration of amenorrhea, vitamin D levels, BMD, or bone microarchitecture measurements. After 1 year of treatment, at the distal tibia there were significantly greater increases in total and trabecular volumetric BMD (v
BMD), cortical area and thickness, and trabecular number in the PATCH versus PILL groups. Trabecular area decreased significantly in the PATCH group versus the PILL and NONE groups. Less robust differences between groups were seen at the distal radius, where percent change in cortical area and thickness was significantly greater in the PATCH versus PILL and NONE groups, and changes in cortical v
BMD were significantly greater in the PATCH versus PILL groups. In conclusion, in young OAs, bone structural parameters show greater improvement after 1 year of treatment with transdermal 17β‐estradiol versus ethinyl estradiol–containing pills, particularly at the tibia. © 2019 American Society for Bone and Mineral Research.
Early Alendronate Can Be Safe during Fracture Healing?
06-11-2019 – Eugene Fung
Effects of Alendronic Acid on Fracture Healing
06-11-2019 – Andrew D Duckworth, Margaret M McQueen, Christopher E Tuck, Jonathan H Tobias, Jeremy Mark Wilkinson, Leela C Biant, Elizabeth Claire Pulford, Stephen Aldridge, Claire Edwards, Chris P Roberts, Manoj Ramachandran, Andrew Richard McAndrew, Kenneth C K Cheng, Phillip Johnston, Nasir H Shah, Philip Mathew, John Harvie, Birgit C Hanusch, Ronnie Harkess, Aryelly Rodriguez, Gordon D Murray, Stuart H Ralston
“Short Sleep Is Associated With Low Bone Mineral Density and Osteoporosis in the Womens Health Initiative”
06-11-2019 – Heather M Ochs‐Balcom, Kathleen M Hovey, Christopher Andrews, Jane A Cauley, Lauren Hale, Wenjun Li, Jennifer W Bea, Gloria E Sarto, Marcia L Stefanick, Katie L Stone, Nelson B Watts, Oleg Zaslavsky, Jean Wactawski‐Wende
ABSTRACTShort sleep duration, recognized as a public health epidemic, is associated with adverse health conditions, yet little is known about the association between sleep and bone health. We tested the associations of usual sleep behavior and bone mineral density (BMD) and osteoporosis. In a sample of 11,084 postmenopausal women from the Womens Health Initiative (WHI; mean age 63.3 years, SD = 7.4), we performed a cross‐sectional study of the association of self‐reported usual hours of sleep and sleep quality (WHI Insomnia Rating Score) with whole body, total hip, femoral neck, and spine BMD using linear regression models. We also studied the association of sleep duration and quality with dual‐energy X‐ray absorptiometry (DXA)‐defined low bone mass (T‐score < −2.5 to <−1) and osteoporosis (T‐score ≤ −2.5) using multinomial regression models. We adjusted for age, DXA machine, race, menopausal symptoms, education, smoking, physical activity, body mass index, alcohol use, physical function, and sleep medication use. In adjusted linear regression models, women who reported sleeping 5 hours or less per night had on average 0.012 to 0.018 g/cm2 significantly lower BMD at all four sites compared with women who reported sleeping 7 hours per night (reference). In adjusted multinomial models, women reporting 5 hours or less per night had higher odds of low bone mass and osteoporosis of the hip (odds ratio OR = 1.22; 95% confidence interval CI 1.03–1.45, and 1.63; 1.15–2.31, respectively). We observed a similar pattern for spine BMD, where women with 5 hours or less per night had higher odds of osteoporosis (adjusted OR = 1.28; 95% CI 1.02–1.60). Associations of sleep quality and DXA BMD failed to reach statistical significance. Short sleep duration was associated with lower BMD and higher risk of osteoporosis. Longitudinal studies are needed to confirm the cross‐sectional effects of sleep duration on bone health and explore associated mechanisms. © 2019 American Society for Bone and Mineral Research.
Extracellular Vesicles From Osteotropic Breast Cancer Cells Affect Bone Resident Cells
05-11-2019 – Alexander Loftus, Alfredo Cappariello, Christopher George, Argia Ucci, Kirsty Shefferd, Alice Green, Riccardo Paone, Marco Ponzetti, Simona Delle Monache, Maurizio Muraca, Anna Teti, Nadia Rucci
ABSTRACTExtracellular vesicles (EVs) are emerging as mediators of a range of pathological processes, including cancer. However, their role in bone metastases has been poorly explored. We investigated EV‐mediated effects of osteotropic breast cancer cells (MDA‐MB‐231) on bone resident cells and endothelial cells. Pretreatment of osteoblasts with conditioned medium (CM) of MDA‐MB‐231 (MDA) cells promoted pro‐osteoclastogenic and pro‐angiogenic effects by osteoblast EVs (OB‐EVs), as well as an increase of RANKL‐positive OB‐EVs. Moreover, when treating osteoblasts with MDA‐EVs, we observed a reduction of their number, metabolic activity, and alkaline phosphatase (Alp) activity. MDA‐EVs also reduced transcription of Cyclin D1 and of the osteoblast‐differentiating genes, while enhancing the expression of the pro‐osteoclastogenic factors Rankl, Lcn2, Il1b, and Il6. Interestingly, a cytokine array on CM from osteoblasts treated with MDA‐EVs showed an increase of the cytokines CCL3, CXCL2, Reg3G, and VEGF, while OPG and WISP1 were downregulated. MDA‐EVs contained m
RNAs of genes involved in bone metabolism, as well as cytokines, including PDGF‐BB, CCL3, CCL27, VEGF, and Angiopoietin 2. In line with this profile, MDA‐EVs increased osteoclastogenesis and in vivo angiogenesis. Finally, intraperitoneal injection of MDA‐EVs in mice revealed their ability to reach the bone microenvironment and be integrated by osteoblasts and osteoclasts. In conclusion, we showed a role for osteoblast‐derived EVs and tumor cell–derived EVs in the deregulation of bone and endothelial cell physiology, thus fueling the vicious cycle induced by bone tumors. © 2019 American Society for Bone and Mineral Research.
Denosumab Prevents Early Periprosthetic Bone Loss After Uncemented Total Hip Arthroplasty: Results from a Randomized Placebo‐Controlled Clinical Trial
04-11-2019 – Andreas Nyström, Demostenis Kiritopoulos, Gösta Ullmark, Jens Sörensen, Marianne Petrén‐Mallmin, Jan Milbrink, Nils P Hailer, Hans Mallmin
ABSTRACTImplant loosening is the most common indication for revision surgery after total hip arthroplasty (THA). Although bone resorption around the implants plays a pivotal role in the pathophysiology of loosening, it is unknown whether potent early inhibition of osteoclasts could mitigate this process and thus reduce the need for revision surgery. We performed a randomized, double‐blind, placebo‐controlled phase 2 trial in 64 patients aged 35 to 65 years with unilateral osteoarthritis of the hip. They underwent surgery with an uncemented THA and were randomized to either two subcutaneous doses of denosumab (n = 32) or placebo (n = 32) given 1 to 3 days and 6 months after surgery. Patients were followed for 24 months. Primary outcome was periprosthetic bone mineral density (BMD) of the hip at 12 months as measured by dual‐energy X‐ray absorptiometry (DXA). In addition, 18F sodium fluoride positron emission tomography/CT (F‐PET) was performed in half of the patients for analysis of periprosthetic standardized uptake value (SUV). Analyses were made according to intention‐to‐treat principles. The trial was registered at Clinical
Trials.gov 2011‐001481‐18, NCT01630941. Denosumab potently inhibited early periprosthetic bone loss. After 12 months, BMD in the denosumab group was 32% (95% confidence interval CI 22–44) higher in Gruen zone 7 and 11% (95% CI 8–15) higher in zones 1 to 7. After 24 months, the difference in BMD between groups had decreased to 15% (95% CI 4–27) in zone 7 and 4% (95% CI 0–8) in zones 1 to 7. In both groups, SUV increased after surgery, but the increase was less pronounced in the denosumab group. Biochemical markers of bone metabolism decreased in the denosumab group in the first 12 months, but a rebound effect with marker concentrations above baseline was observed after 24 months. Denosumab potently prevents early periprosthetic bone loss after uncemented THA; however, the effect diminishes after discontinuation of treatment. Further research is needed to determine whether this bone loss will prove to be of clinical importance and, if so, whether the positive effect observed in this study could be preserved by either prolonged treatment with denosumab or additional antiresorptive treatment. © 2019 American Society for Bone and Mineral Research. © 2019 American Society for Bone and Mineral Research.
A Geriatric Exercise Program May Yield Multiple Benefits
31-10-2019 – Jodi Dowthwaite
A CTGF‐RUNX2‐RANKL Axis in Breast and Prostate Cancer Cells Promotes Tumor Progression in Bone
31-10-2019 – Bongjun Kim, Haemin Kim, Suhan Jung, Aree Moon, Dong‐Young Noh, Zang Hee Lee, Hyung Joon Kim, Hong‐Hee Kim
ABSTRACTMetastasis to bone is a frequent occurrence in patients with breast and prostate cancers and inevitably threatens the patients quality of life and survival. Identification of cancer‐derived mediators of bone metastasis and osteolysis may lead to novel therapeutic strategies. In this study, we established highly bone‐metastatic PC3 prostate and MDA‐MB‐231 (MDA) breast cancer cell sublines by in vivo selection in mice. In bone‐metastatic cancer cells, the expression and secretion of connective tissue growth factor (CTGF) were highly upregulated. CTGF knockdown in bone‐metastatic cells decreased invasion activity and MMP expression. RUNX2 overexpression in the CTGF knockdown cells restored the invasion activity and MMP expression. In addition, CTGF increased RUNX2 protein stability by inducing its acetylation via p300 acetyl transferase. The integrin αvβ3 receptor mediated these effects of CTGF. Furthermore, CTGF promoted RUNX2 recruitment to the RANKL promoter, resulting in increased RANKL production from the tumor cells and subsequent stimulation of osteoclastogenesis from precursor cells. In addition, animal model with injection of CTGF knocked‐down prostate cancer cells into 6‐week old BALB/c male mice showed reduced osteolytic lesions. More importantly, the expression levels of CTGF and RANKL showed a strong positive correlation in human primary breast tumor tissues and were higher in bone metastases than in other site metastases. These findings indicate that CTGF plays crucial roles for osteolytic bone metastasis both by enhancing invasiveness of tumor cells and by producing RANKL for osteoclastogenesis. Targeting CTGF may lead to the development of effective preventive and therapeutic strategies for osteolytic metastasis. © 2019 American Society for Bone and Mineral Research.
Increased Fracture Risk in Women Treated With Aromatase Inhibitors Versus Tamoxifen: Beneficial Effect of Bisphosphonates
31-10-2019 – Marta Pineda‐Moncusí, Natalia Garcia‐Giralt, Adolfo Diez‐Perez, Sonia Servitja, Ignasi Tusquets, Daniel Prieto‐Alhambra, Xavier Nogués
ABSTRACTAromatase inhibitors have been associated with accelerated bone loss and an increased risk of osteoporotic fractures. Currently, bisphosphonates are recommended to reduce fracture risk in these patients. The aim of this study is to evaluate the fracture risk in breast cancer patients receiving aromatase inhibitors, compared to tamoxifen users, and to assess the effectiveness of oral bisphosphonates in reducing fracture risk. We performed an observational cohort study up to 10 years of follow‐up. Data were extracted from primary care records in a population database. Women diagnosed with breast cancer between 2006 and 2015 and treated with tamoxifen or aromatase inhibitors (n = 36,472) were stratified according to low (without osteoporosis diagnosis nor bisphosphonates exposure) or high (with osteoporosis and/or treated with bisphosphonates) fracture risk. Cox models were used to calculate hazard ratios (HR 95% CI) of fracture from the propensity score–matched patients. Sensitivity analyses account for competing risk of death were performed (subdistribution hazard ratio SHR 95% CI). In postmenopausal women, fracture risk in aromatase inhibitor users showed an HR 1.40 95% CI,1.05 to 1.87 and SHR 1.48 95% CI, 1.11 to 1.98, compared to tamoxifen. Observing aromatase inhibitors patients at high risk of fracture, bisphosphonate‐treated patients had an HR 0.73 95% CI, 0.51 to 1.04 and SHR 0.69 95% CI, 0.48 to 0.98 compared to nontreated. In conclusion, fracture risk in postmenopausal women during aromatase inhibitor treatment, in real‐life conditions, was >40% compared to tamoxifen, corroborating previous randomized controlled trials results. In high‐risk patients, bisphosphonate users had lower significant fracture incidence during aromatase inhibitor therapy than nonbisphosphonate users. Monitoring fracture risk and related risk factors in aromatase inhibitor patients is advisable. © 2019 American Society for Bone and Mineral Research.
Effects of Long‐Duration Spaceflight on Vertebral Strength and Risk of Spine Fracture
31-10-2019 – Katelyn Burkhart, Brett Allaire, Dennis E Anderson, David Lee, Tony M Keaveny, Mary L Bouxsein
ABSTRACTAlthough the negative impact of long‐duration spaceflight on spine BMD has been reported, its impact on vertebral strength and risk of vertebral fracture remains unknown. This study examined 17 crewmembers with long‐duration service on the International Space Station in whom computed tomography (CT) scans of the lumbar spine (L1 and L2) were collected preflight, immediately postflight and 1 to 4 years after return to Earth. We assessed vertebral strength via CT‐based finite element analysis (CT‐FEA) and spinal loading during different activities via subject‐specific musculoskeletal models. Six months of spaceflight reduced vertebral strength by 6.1% (−2.3%, −8.7%) (median interquartile range) compared to preflight (p < 0.05), with 65% of subjects experiencing deficits of greater than 5%, and strengths were not recovered up to 4 years after the mission. This decline in vertebral strength exceeded (p < 0.05) the 2.2% (−1.3%, −6.0%) decline in lumbar spine DXA‐BMD. Further, the subject‐specific changes in vertebral strength were not correlated with the changes in DXA‐BMD. Although spinal loading increased slightly postflight, the ratio of vertebral compressive load to vertebral strength for typical daily activities remained well below a value of 1.0, indicating a low risk of vertebral fracture despite the loss in vertebral strength. However, for more strenuous activity, the postflight load‐to‐strength ratios ranged from 0.3 to 0.7, indicating a moderate risk of vertebral fracture in some individuals. Our findings suggest persistent deficits in vertebral strength following long‐duration spaceflight, and although risk of vertebral fracture remains low for typical activities, the risk of vertebral fracture is notable in some crewmembers for strenuous exercise requiring maximal effort. © 2019 American Society for Bone and Mineral Research.
Association of Mineral Bone Disorder With Decline in Residual Kidney Function in Incident Hemodialysis Patients
30-10-2019 – Yu‐Ji Lee, Yusuke Okuda, John Sy, Yoshitsugu Obi, Duk‐Hee Kang, Steven Nguyen, Jui Ting Hsiung, Christina Park, Connie M Rhee, Csaba P Kovesdy, Elani Streja, Kamyar Kalantar‐Zadeh
ABSTRACTAbnormalities of mineral bone disorder (MBD) parameters have been suggested to be associated with poor renal outcome in predialysis patients. However, the impact of those parameters on decline in residual kidney function (RKF) is uncertain among incident hemodialysis (HD) patients. We performed a retrospective cohort study in 13,772 patients who initiated conventional HD during 2007 to 2011 and survived 6 months of dialysis. We examined the association of baseline serum phosphorus, calcium, intact parathyroid hormone (PTH), and alkaline phosphatase (ALP) with a decline in RKF. Decline in RKF was assessed by estimated slope of renal urea clearance (KRU) over 6 months from HD initiation. Our cohort had a mean ± SD age of 62 ± 15 years; 64% were men, 57% were white, 65% had diabetes, and 51% had hypertension. The median (interquartile range IQR) baseline KRU level was 3.4 (2.0, 5.2) m
L/min/1.73 m2. The median (IQR) estimated 6‐month KRU slope was −1.47 (−2.24, −0.63) m
L/min/1.73 m2 per 6 months. In linear regression models, higher phosphorus categories were associated with a steeper 6‐month KRU slope compared with the reference category (phosphorus 4.0 to <4.5 mg/d
L). Lower calcium and higher intact PTH and ALP categories were also associated with a steeper 6‐month KRU slope compared with their respective reference groups (calcium 9.2 to <9.5 mg/d
L; intact PTH 150 to <250 pg/m
L; ALP <60 U/L). The increased number of parameter abnormalities had an additive effect on decline in RKF. Abnormalities of MBD parameters including higher phosphorus, intact PTH, ALP and lower calcium levels were independently associated with decline in RKF in incident HD patients. © 2019 American Society for Bone and Mineral Research. © 2019 American Society for Bone and Mineral Research.